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ABSTRACT
MODULATING NANOPARTICLE-PROTEIN INTERACTIONS THROUGH
COVALENT OR NONCOVALENT APPROACH FOR BIOMEDICAL
APPLICATIONS
FEBRUARY 2020
JINGJING GAO
B.A., SOUTH CENTRAL UNIVERSITY FOR NATIONALITIES
M.A., SHANGHAI JIAO TONG UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Sankaran Thayumanavan
Discoveries at the interface of chemistry, biology, and materials science has emerged as a
powerful route to impact life science in this century. My research in the Thayumanavan
group is focused on problems at this interface. A common theme of all the six projects is
the use of modern synthetic organic chemistry to build interesting, novel macromolecules
which are chemically rich, to study the molecular self-assembly behavior in solution and
then translate to solve problems in biomedical area. By addressing the design challenge to
prepare novel amphiphiles with desired functional groups, controlled molecular weight and
the ability to respond to a broad range of stimuli, especially protein and enzyme, we have
achieved the following aims that showed great potential for biomedical applications such
as sensing, imaging and drug delivery: a) we have systematically studied the molecular
weight effects and hydrophilic-hydrophobic balance effects on enzyme induced
supramolecular disassembly, which could provide tunability over covalent and noncovalent guest molecules release kinetics. b) Other than single stimuli-responsive system,
we outlined a simple and new strategy was outlined for amphiphilic nanoassemblies to

vii

respond to a combination of intrinsic trigger protein and extrinsic trigger light in the logic
gated fashion. c) Considering biomedical applications based on these nanoassemblies, we
then try to solve the most critical step for nanomedicine, which is specific targeting. Unlike
common strategies relying on complementary ligands, we showed a cellular AND gate for
highly selective cell accumulation by covalently masking and unmasking ligands on block
copolymer based nanogels, such an ability will facilitate tumor imaging and diagnostics; d)
We then showed a self-immolative nanogel platform to deliver hydrophobic drugs, with
accessible functional group present on the surface, this nanogel can be easily functionalized
with various receptors for targeted delivery into cytosol and subcellular organelles; e) We
designed a novel supramolecular approach that selectively transports water-soluble
globular proteins from an aqueous phase to the water-pool of a reverse micelle in an apolar
organic phase. Proteins can maintain functions after crossing an incompatible solvent
interface, which opens new possibilities for application of supramolecular assemblies in
sensing, diagnostics and catalysis. f) following these findings, we designed an enzyme
nanoreactor for catalysis in apolar solvent and introduce crosslinks in the molecular
assemblies, we will further try to control substrate permeability into the assembly to
engineer unnatural selectivity in enzymes.
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CHAPTER 1
INTRODUCTION
1.1 Supramolecular assembly
Amphiphilic molecules, ranging from small molecule surfactants, oligomers, dendrimers
to higher molecular weight polymers, could aggregate in a self-organized fashion.1-5 The
self-assembled aggregates maintain an equilibrium with respecting monomers, could
generate various morphologies such as micelles, vesicles, fibers and helical shape based on
the molecule packing parameters (Figure 1.1).

Figure 1.1 Self-assembled structures from amphiphilic molecules. Reproduced from ref. 3
The self-assembly process is usually driven by non-covalent interactions such as van der
waals forces, pi-pi interactions, hydrogen-bonding, electrostatic interactions and
hydrophobic effects.6-7 These reversible interactions make self-assembly a dynamic
process

in response to environment cues. But amphiphiles must reach a certain

concentration to form assemblies, which is called its critical aggregation concentration
(CAC). Small molecular weight surfactants usually possess a relative high CAC value
compare with higher molecular weight amphiphiles, due to its fast exchange with
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corresponding aggregates. Surfactants have been often used as detergents, emulsifiers,
foaming and anti-foaming agents. Self-assembled structures from higher molecular weight
amphiphiles ten to be more thermodynamically stable, which could find interesting
applications in a variety of areas such as sensing, drug delivery and diagnostics. Since
amphiphilic molecules contain two distinctly different components: hydrophilic moiety
and hydrophobic moiety, when they assemble in aqueous phase, the hydrophilic functional
groups would present on the surface of the assemblies to form the primary interface with
the solvent. Variations of the functional groups that would further induce changes in
hydrophobic-hydrophilic balance of the assemblies could provide a lot of interesting
applications. This thesis here will introduce different type of assemblies formed by
dendrimers, oligomers and also polymers and potential applications.
1.2 Protein responsive supramolecular assemblies
Stimuli-responsive systems, which could respond to a certain environment stimulus, have
raised particular interest in the past few decades because they can easily find use in a very
broad range of applications.8-10 For example, one could design supramolecular assemblies
that is sensitive to pH change and yield a response in the form of guest molecule release.
Various types of stimuli have been used as a trigger to induce the response of assemblies
(Figure 1.2). In the context of biology, the triggers can be classified into two categories:
extrinsic stimuli and intrinsic stimuli. Extrinsic stimuli include light, magnetic field,
ultrasound, electric field and mechanical forces; intrinsic stimuli include pH, redox,
temperature, nucleic acids, sugars, enzyme and protein. Current studies have reported a lot
of advances in secondary imbalances such as pH, redox and temperature, however those
are just secondary imbalances in biology. In the prospective of biomedicine, we are more
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interested in developing protein or enzyme sensitive assemblies, because most of the
pathological imbalances are directly caused by aberrant protein activity.

Figure 1.2 Various types of stimuli triggers. Reproduced from ref. 11. Copyright © 2014
Elsevier B.V. All rights reserved.
First, we targeted assemblies that are capable of responding to enzyme. Past few decades
have witnessed considerable progress in the field of enzyme-responsive assemblies.12-17
Typically these assemblies possess enzyme-reactive moieties in the form of labile linkages
among the main or side chains of the molecular scaffold. Therefore, enzyme-catalyzed
reactions induced chemical structural changes of the synthetic molecules could further lead
to morphological transitions of these assemblies. We have shown several dendrimer
amphiphiles that could undergo enzyme-induced disassembly by installing enzymeresponsive units onto the hydrophobic core of the micelle-like assemblies 15, we envisaged
that the equilibrium between the unimeric state and the aggregate state must be involved
in this process (Figure 1.3). We have been interested in investigating how the reaction
kinetics and the ensuing change in the host-guest characteristics would be affected by

3

tuning unimer-aggregate equilibrium to alter the assemblies’ accessibility to the enzyme.
Moreover, we were interested in identifying as to how structural changes in host assemblies,
induced by an enzyme, would affect rate of disassembly and kinetics of guest molecule
release.

Figure 1.3 Schematic representation of enzyme-induced disassembly of dendritic micelles
While the enzyme-sensitive disassembly is dictated by a covalent and irreversible
modification of the assemblies, supramolecular disassembly based on noncovalent
interactions is also of great interest and a challenge, since a lot of disease-relevant proteins
do not have known enzymatic activity. We envisaged that non-covalent binding between a
ligand and protein could be utilized to develop a non-enzymatic protein responsive
assembly. We designed a ligand-bearing amphiphilic dendron that formed stable
assemblies but disassembled upon binding the target protein (Figure 5).18 We hypothesized
that the HLB of an assembly was significantly different from that of the protein−assembly
complex, because the protein was rather large in molecular weight and was much more
hydrophilic compared to the amphiphile. We actually found that ligand bearing assemblies
were disrupted only by a target protein but not by other non-complementary proteins,
indicated by the size decrease and guest molecule release.

4

Figure 1.4 (a) Illustration of protein-induced disassembly; protein binds to the ligand
present on the dendron’s hydrophilic face, leading to the formation of an overall
hydrophilic protein−dendron complex and micelle disassembly. (b) Structure of G2
dendron with enzyme responsive functional group
1.3 AND gated supramolecular disassembly
In addition to assemblies that can be triggered by a single stimulus, recent interests have
been attracted by multiple stimuli-responsive systems, because they can provide enhanced
selectivity in stimuli-responsiveness, which is critical in targeted delivery.10 In engineering
the combinations of these two triggers, we were inspired by the molecular logic gates
proposed and studied over past couple of decades.19-23 While there have been many reports
on molecular logic gates involving small molecules, such gated strategies in nanoscale
5

assemblies are relatively limited, especially the ‘AND gate’. We have introduced a dual
protein stimuli-responsive AND gate design to amphiphilic dendrimers, where the system
only responded to the concurrent presence of two different proteins (Figure 1.5).24 A
dendron molecule was designed containing an enzyme sensitive coumarin ester as the
hydrophobic moiety and a protein-specific 2,4-DNP ligand as part of the hydrophilic PEG
moiety. The release of the fluorescent umbelliferone from the coumarin ester cleavage due
to the dual protein triggers was indeed found to be 26 times faster than that due to the
enzyme alone.

Figure 1.5 (a) Illustration of dual responsive system. (b) Enzyme induced change in the
amphiphilic dendron accompanied by fluorophore release.24
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1.4 Stimuli-responsive assemblies for targeting and drug delivery
Traditional routes of drug administration include systemic delivery, oral delivery and local
injection, none of these methods are satisfying because they usually generate side effects
due to drug degradation during circulation, undergo harsh environment and cause damage
to surrounding tissues. To overcome these shortcomings, drug delivery system that can
deliver the required dose of drugs to the specific disease site come into the stage. Our group
has outlined the figure of merits for an ideal drug delivery system

25

: (a) it has to be

nontoxic to human body; (b) it should be able to provide stable guest molecule
encapsulation; (c) the delivery system could respond to certain stimuli so that the drug
molecules can be released in presence of the trigger; (d) the carrier should be able to
selectively accumulate at the disease site through either passive targeting or active
targeting.

Figure 1.6 Figure of merits for an ideal drug delivery vehicle.25
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Among these features, targeting specific disease cells is critical for a drug delivery system
to be applicable in-vivo. It has been suggested that drug carriers with a size range of 10200 nm may exhibit preferential accumulation in the context of tumors, mainly due to the
extravasation of drug carriers into solid tumor tissues and prevent lymphatic drainage, the
so-called enhanced permeation and retention (EPR) effect.26-27 Drug carrier relying on this
passive targeting has been clinically used and showed tumor accumulation, reduced
clearance and reduced cardiotoxicity.28-29

Figure 1.7 Cartoon representation of passive and active targeting mechanisms
On the contrary of passive targeting, active targeting rely on the specific binding to the
cancer cell surfaces. By incorporation of specific ligands to the nanocarriers that are
complementary to receptors overexpressed on tumor cell surface, these nanocarriers
promises to target cancer cells more effectively than EPR effect alone. Cellular targets
usually used in the active targeting strategy involve the targeting of cancer cells and tumour
endothelium receptors including transferrin, folate, epidermal growth factor receptor,
8

vascular endothelial growth factor, αvβ3 integrins and the Vascular Cell Adhesion
Molecule-1 (VCAM-1) or matrix metalloproteinases (MMP's).
The amphiphiles formed nanoassemblies we have introduced hold great potential for
targeting and drug delivery because their container properties. Drugs could be noncovalently encapsulated by the nanoassembly and be protected from harsh environment.
By installing stimuli-responsive functional groups, the drug molecules could be released
in a controlled fashion. We have reported a nanogel system which contain a crosslinkable
core and hydrophilic shell, which provide stable encapsulation of hydrophobic drug
molecules.30-31 The disulfide crosslink could lock the drug molecules and then release them
at intracellular GSH concentration. Post-modification through disulfide exchange enable
ligands decoration so the nanogels could be armed with active targeting capabilities.

Figure 1.8 Nanogel design and preparation for target delivery.30-31

9

1.5 Thesis overview

This thesis will focus on design and synthesis of amphiphilic assemblies that hold great
potential in areas such as sensing, cell targeting and drug delivery. In Chapter 2, we
outlined a simple and new strategy to design amphiphilic nanoassemblies that could
respond to a combination of intrinsic trigger protein and extrinsic trigger light in an logic
gated (AND, OR, NOT) strategy, supramolecular disassembly and guest molecule release
could then be achieved in a controlled fashion.
Chapter 3, we have systematically studied the molecular weight effects and hydrophilichydrophobic balance effects on enzyme induced supramolecular disassembly, which
provide insights into the molecular design of enzyme-responsive systems.
Chapter 4, we have designed a self-immolative nanogel platform for hydrophobic drugs
delivery, with accessible functional group present on the surface, this nanogel can be easily
functionalized with various receptors for targeted delivery.
Chapter 5, we showed a novel approach for highly selective cell accumulation was
designed by covalently masking and unmasking ligands on block copolymer based
nanogels, such an ability will facilitate tumor imaging.
Chapter 6, we designed a novel supramolecular approach that selectively transports watersoluble globular proteins from an aqueous phase to the water-pool of a reverse micelle in
an apolar organic phase. Proteins can maintain functions after crossing an incompatible
solvent interface, which opens new possibilities for application of supramolecular
assemblies in sensing, diagnostics and catalysis.
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Chapter 6 showed the design of an enzyme nanoreactor for catalysis in apolar solvent and
how to introduce crosslinks in the molecular assemblies, we will further try to control
substrate permeability into the assembly to engineer unnatural selectivity in enzymes.
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CHAPTER 2
PHOTOACTIVATION OF LIGANDS FOR EXTRINSICALLY AND
INTRINSICALLY TRIGGERED DISASSEMBLY OF AMPHIPHILIC
NANOASSEMBLIES
Adapted with permission from Gao, J.; Liu, X.; Secinti, H.; Jiang, Z.; Munkhbat, O.; Xu,
Y.; Guo, X.; Thayumanavan, S. Photoactivation of Ligands for Extrinsically and
Intrinsically Triggered Disassembly of Amphiphilic Nanoassemblies. Chem. Eur. J. 2018,
24, 1789-1794. © Copyright 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
2.1 Introduction
Supramolecular nanoassemblies that predictably respond to an environmental change
have been of interest due to their implications in areas that range from material science to
biomedicine

1-5

. When designing molecular assemblies that have the potential to impact

biomedicine, the input triggers can be classified into two main categories: extrinsic and
intrinsic inputs.6-10 Extrinsic triggers have the advantage of offering external
spatiotemporal control over the change in the properties of a molecular assembly, e.g.
shining light at a specific location and time to disrupt a supramolecular assembly. 11-22 On
the other hand, intrinsic triggers are directly correlated with an aberrant biological
condition and therefore have the opportunity to be selective, e.g. lower pH at the
extracellular space of disease tissues.23-27 Although both these systems present
complementary advantages, the specificity offered by either of these systems by itself is
insufficient. Therefore, a viable strategy would involve systems that would respond to a
specific combination of extrinsic and intrinsic stimuli. We present a simple, new
supramolecular approach that responds to a specific combination of extrinsic and intrinsic
stimuli.
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We use proteins as the intrinsic trigger in our studies here, although the often-targeted
intrinsic triggers are pH, reducing conditions, and reactive oxygen species.28-34 Proteins are
challenging and interesting as inputs, because of their structural and functional fragility
and because they are considered to be the primary cause of pathological imbalances in
biology.35-39 We use light as the extrinsic trigger in these studies. In engineering the
combinations of these two triggers, we were inspired by the molecular logic gates proposed
and studied over past couple of decades.40-47 While there have been many reports on
molecular logic gates involving small molecules,48-54 such gated strategies in nanoscale
assemblies are relatively limited.55 We are particularly interested in developing systems
that predictably respond to dual inputs, based on protein and light (Figure 2.1).

Figure 2.1 Schematic representation of protein and light responsive nanoassembly.
2.2 Results and discussion
2.2.1 Proof of concept on small molecules
First, we targeted the design of a molecular assembly that would respond only in the
presence of a specific protein and light, but not in the presence of either of these inputs by
themselves or in their absence. Such a system is interesting, as they offer the best
opportunity to be specific, because it requires the concurrent presence of two different
stimuli. For the protein, we used bovine carbonic anhydrase (bCA). Primary aryl
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sulfonamides are well established ligands for this protein, where the active site zinc is
known to be engaged with the sulfornamide moiety.56-58 Examination of the structure of
this binding interaction suggests that derivatizing the amino moiety of the sulfonamide
group with an alkyl unit would cause this molecule to be not a good ligand for bCA. If
such a substituent were to be removed in the presence of light, then the ligand is rendered
activatable by light. Our design hypothesis is then that if such a functional group were to
be then incorporated onto a protein-responsive assembly, then the assembly would respond
only if there is both light and protein present, as shown in Figure 2.1.
Scheme 2.1 Photo-induced cleavage of compound 1 to expose sulphonamide ligand 2

Figure 2.2 1H NMR spectra of compound 1 in D-DMSO at various UV irradiation periods.
The gradual decrease of peaks at 8.49 and 4.36 ppm, which is corresponding to imino and
methylene group, indicated the photo-cleavage of o-nitrobenzyl group.
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To test this hypothesis, we first tested whether small molecule sulfonamide ligand can be
protected by an o-nitrobenzyl moiety, which can then be released in the presence of light.
Accordingly, we synthesized the molecule 1 and evaluated the possibility of deprotection
of the nitrobenzyl moiety due to light irradiation at 365 nm (Figure 2.1). Indeed, 1H NMR
and LC-MS studies showed that the sulfonamide ligand was fully liberated to afford the
sulfonamide ligand 2, in response to UV irradiation (Figure 2.2, 2.3). We also tested
molecules 1 and 2 as the ligands for bCA using a 5-(Dimethylamino)-1naphthalenesulfonamide (DNSA) in a competitive displacement assay, the fluorescence
emission at 460 nm formed by DNSA-bCA complex indicates whether DNSA is
replaced.11 Our studies showed that when the ligand was masked in 1, it did not
competitively remove DNSA, while the photo-cleaved product 2 was able to displace
DNSA at a molar ratio of 1:1 for bCA and DNSA (Figure 2.4).

Figure 2.3 LC-ESI-MS results of compound 1 upon UV irradiation. Green peak (m/z =
335.0) is corresponding to compound 1. Pink peak (m/z = 200.0) is corresponding to
compound 2: 4-carboxylbenzene-sulfonamide. This result indicated that sulfonamide is
generated after UV irradiation.
18
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Figure 2.4 Emission spectra of bCA, DNSA, bCA-DNSA complex, bCA-2 complex, CA1 complex irradiated by UV, competitive binding between 2 and DNSA.
2.2.2 Protein AND light gated disassembly and guest release
To generate a nanoassembly that would predictably respond only to the concurrent
presence of light irradiation and the protein, we took the structural components of molecule
1 and install it into an amphiphilic dendrimer. The molecular structure that potentially
serves this purpose is shown in Figure 2.5b as 3. The facially amphiphilic trimer contains
an alkyl chain as the hydrophobic moiety and an oligoethylene glycol (OEG) chain as the
hydrophilic moiety in each of the repeat units. The key functional group, N-(o-nitrobenzyl)
benzene sulfonamide, is clicked on to the central unit on the hydrophilic face of the
amphiphile using the Huisgen cycloaddition reaction. This amphiphile is known to
aggregate to form nanoassemblies, which could then disassemble in response to a ligandprotein binding because of the change in the hydrophilic-lipophilic balance (HLB) upon
protein binding. We also hypothesized that this nanoassembly would disassemble only in
response to both light and protein, but not to just one of these two inputs. When the
19

assembly is irradiated with light, the sulfonamide moiety would be liberated; this change
however would not be sufficient to change the HLB of the assembly. Similarly, since the
ligand moiety is masked, it would be unavailable for the binding-induced disassembly in
response to the protein. However, in the presence of both light and the protein, the
nanoassembly should disassemble as the light would unmask the ligand, binding of which
to the protein would cause a significant change in the HLB of the amphiphile.

Figure 2.5. (a) Schematic representation of protein AND light gated disassembly and
guest release, (b) Molecular structure of 3.
Prior to testing this hypothesis, we characterized the nanoassembly, formed from molecule
3. Synthetic details and the molecular characterization are shown in the SI. Since 3 contains,
the nanoassembly formed would be an amphiphilic assembly, the critical aggregation
concentration (CAC) can be estimated using the possibility of incorporating a hydrophobic
molecule within the interiors of the assembly. The CAC for 3 was found to be ~36 μM. To
assess the size of the nanoassembly formed, an aqueous solution of 3 was assessed using
dynamic light scattering (DLS), at a concentration above its CAC (50 μM). The
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amphiphilic nanoassembly was found to have an apprarent hydrodynamic diameter of >120
nm (Figure 2.6a). The spherical morphology of the assembly was ascertained using
transmission electron microscopy (TEM) (Figure 2.6c) and atomic force microscopy (AFM)
(Figure 2.7). Size from TEM images showed that the observed aggregates are

Figure 2.6 (a) Apparent hydrodynamic diameter(DH, app) of nanoassembly formed by 3 (50
μM) determined by one-angle dynamic light scattering, and 3 in presence of bCA and UV
after 48h, (b) DH, app of nanoassembly 3 in presence of UV, bCA, UV and BSA, TEM
images of 3 (50 μM) in presense of (c) no inputs, (d) UV light, (e) bCA, (f) bCA and UV
light, (g) DiI release from 50 μM 3 solution in response to UV and bCA, (h) Plot of %
release of DiI.
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slightly lower than those from DLS, this difference is likely due to the shrinkage of the
particles in the dry state or due to overestimation of the size of the particles in DLS as it
also includes hydration shells around the particles.
Next, to test our hypothesis that the nanoassembly from 3 would be sensitive to the
concurrent presence of both light and proteins, we treated a 50 µM solution of 3 with 365
nm light irradiation for 15 minutes and 60 µM bCA. We were gratified to find that the size
of the assembly reduced from >120 nm to <10 nm (Figure 2.6a). To fully test whether this
is indeed a response to the combination of these two inputs, effects of the light irradiation
and the presence of bCA were tested independently. In both these cases, there was no
discernible change in the size of the assembly, compared to the assembly of 3 itself (Figure
2.6b). The size change in the presence of both stimuli, and lack thereof in the presence of
either of these stimuli, were also confirmed by TEM (Figure 2.6c-f) and AFM (Figure 2.7).
These results provided the first indicator that the system is only responsive to the presence
of both stimuli.

Figure 2.7 AFM images of 3 (50 μM) supramolecular micellar structures in aqueous
solution in presence of (a) no inputs, (b) bCA, (c) UV light, (d) bCA and UV light.
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To test these findings further, we utilized the host-guest properties of the nanoassembly.
Since 3 forms amphiphilic aggregates with a hydrophobic interior in the aqueous phase, it
can function as a nanocontainer to host water-insoluble guest molecules. We envisaged
that by taking advantage of this container-like feature and employing AND logic inputs to
the nanoassemblies, we will be able to regulate the guest release profile. Here, we use 1,1'dioctadecyl-3,3,3'3'-tetramethyl-indocarbocyanine perchlorate (DiI), as the guest molecule
to be entrapped inside the hydrophobic interior of 3. Encapsulation of DiI in this assembly
was found to be quite stable with time, where there was a <10% change in the characteristic
absorption of DiI over 48 hours (Figure 2.6h). Similarly, when the 50 µM solution of 3
was irradiated with light at 365 nm or when it was treated with 60 µM concentration of
bCA,the change in absorption peak was small and indistinguishable from the assembly in
the absence of any stimulus (Figure 2.6h). Interestingly however, a rather dramatic
decrease in DiI absorption was observed in the presence of both light and bCA, where ~60%
of the guest molecules were released from the assembly in ~6 hours and >80% of the
molecules were released in 48 hours (Figure 2.6g, h). These data are all consistent with our
hypothesis that our nanoassembly is programmed to respond only in the presence of both
stimuli. However, it is important to show that the presumed disassembly and guest release
is indeed due to specific protein-ligand binding. To test the specificity of the protein-ligand
binding, we applied UV irradiation and bovine serum albumin (BSA), a protein that has no
specific interaction with sulfonamide, as the simultaneous inputs to investigate the size
transformation and guest release. Indeed, there was neither any change in the size of the
nanoassembly nor was there any discernible guest release over 48 h. These results further
validate that the assembly is specific in response to bCA.
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Figure 2.8. (a) Molecular structure of 4, (b) DH, app of 4 nanoassembly (concentration of 4
= 50 μM); (c) Plot of % release of DiI from 50 μM 4 solution.
Also, we were interested in another control experiment, where we utilize a structurally
related amphiphile forms a similar nanoassembly, but lacks the features that respond to
light or to the specific protein. In this case, we prepared the trimeric amphiphile, 4, in which
every unit contains both hydrophobic alkyl chains and hydrophilic PEG moieties without
any light sensitive moieties or protein-binding ligand functionalities. This molecule, too,
forms a similarly sized nanoassembly in aqueous phase. Similar to the methods above, we
studied the effects of individual and concurrent orthogonal inputs of UV light and bCA
protein. No size transition or discernible guest release were observed, independent of
whether a single input, no input, or both inputs were applied (Figure 2.8b and c). These
results validate that the introduction of N-(o-nitrobenzyl) benzene sulfonamide ligand is
critical for realizing the observed AND-gated disassembly and guest release.
2.2.3 Protein OR light gated disassembly and guest release
In dual responsive logic-gated systems, the next challenge in designing nanoscopic systems
involves the OR gate, where a nanoassembly can respond to either of the inputs. To address
this design challenge, we designed and synthesized the amphiphile 5, shown in Figure 2.9.
This molecule contains a sulfonamide moiety in the middle repeat unit on the hydrophilic
face of the amphiphile, similar to 3, but the bCA-ligand is present here in its unmasked
24

form. At the two terminal units, the hydrophobic decyl chain is linked to the trimeric
scaffold using a photo-responsive o-nitrobenyzl ester linker. Synthetic details and are
shown in the SI. We envisage here that when 5 is exposed to UV light, photo-induced
cleavage of the nitrobenzyl ester will disconnect the long hydrophobic chain from the
amphiphilic oligomer, while concurrently generating a carboxylic acid moiety. This
transformation should render the entire oligomer much more hydrophilic, thus triggering
disassembly. On the other hand, when treated with bCA, the already unmasked and
available sulfonamide ligand should bind to the protein efficiently, causing a change in the
HLB of the amphiphile to result in disassembly.

Figure 2.9. (a) Schematic representation of OR logic gated disassembly and guest release,
(b) Molecular structure of 5.
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To test these design hypotheses, the size transformation of a solution of 5 was evaluated
using DLS. As shown in Figure 1.10e, either UV light or the bCA protein inputs induce a
size change in the nanoassembly from ~150 nm to ~10 nm. TEM images of D2 before and
after applying one or both inputs further confirm the disassembly event (Figure 2.10a-d).
We also tested the host-guest properties of the assembly in the presence of these stimuli.
Indeed, the DiI guest encapsulated in the D2 nanoassembly was released, when exposed to
the bCA protein or the UV irradiation (Figure 2.10f). Note that the extent of molecular
release with the protein binding is smaller than that of unmasked 3. This is expected,
because the overall hydrophobicity of the interior of the assembly from 5 is significantly
higher than that from 3, because of the introduction of additional aromatic units in the two
of the three hydrophobic units. In fact, aromatic-aromatic interactions have been shown to
have a substantial effect on the stability of encapsulation of molecules in these
nanoassemblies.12 Removal of these hydrophobic units, followed by treatment with the
protein brings the guest release profile, comparable to that found with the unmasked 3.

Figure 2.10. TEM images of 5 (50 μM) in presense of (a) no inputs, (b) UV light, (c) bCA,
(d) bCA and UV light; (e) DH, app of 5 nanoassembly in response to UV and bCA, (f) Plot
of % release of DiI.
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2.3 Summary
To summarize, we have demonstrated a set of amphiphilic supramolecular assemblies that
can disassemble in the presence of an extrinsic physical stimulus (light) and an intrinsic
biological stimulus (protein). Since these nanoassemblies are capable of sequestering
hydrophobic guest molecules, the host-guest properties of the assemblies are also
compromised in the presence of these inputs. We outline molecular designs that can
respond to the presence of either one or both of these stimuli, as well as that would respond
only to the concurrent presence of both stimuli. The latter system was developed by caging
a protein-specific ligand with a photo-protecting group that masks the ligand from being
available for protein binding and thus preventing binding-induced disassembly. Therefore,
the nanoassembly requires the concurrent presence of both light and the specific protein
for programmed disassembly. In the former scenario, where the nanoassembly responds to
either of the inputs, the disassembly was achieved by strategically placing the lightresponsive moieties and the protein-responsive moiety in two different parts of the
amphiphilic building block. As controlled responses to the concurrent presence of two
different stimuli present the possibility of substantially increasing specificity in responses,
the design insights provided here will find use in the design of novel protein-responsive
drug delivery and controlled-release systems.
2.4 Experimental procedures
2.4.1 Materials and general methods
All the reagents were from commercial source and used as received. 1H NMR and 13C
NMR spectra were recorded on a Bruker DPX-400 MHz NMR spectrometer using the
residual proton resonance of the solvent as the internal standard. All molecules without
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characterization data mentioned below were synthesized through well-established
synthesis procedures previously reported by our group.

[59-61]

UV-vis absorption spectra

were obtained by a Carry 100 Scan spectrometer. Fluorescence spectra were recorded on a
PerkinElmer LS 55 spectrofluorimeter. Mass spectrometric data were collected by
Capillary LC (Thermo Dionex Ultimate 3000)-ESI-MS (Bruker AmaZon quadrupole ion
trap).
Dynamic Light Scattering (DLS) Study: For the DLS measurements, 2 μmol of 3, 4 or 5
was dissolved in 10 mL PBS buffer (pH 7.4, 10 mM) and stirred at 4 oC for overnight and
then stored in room temperature as 200 μM stock solution. Then these oligomeric
amphiphile solutions were diluted to 50 μM with PBS buffer and filtered using hydrophilic
membrane (pore size 0.450 µm) before experiment was performed. The diluted samples
were treated with UV irradiation (Black Ray UV lamp, 365 nm, 115 V ~ 60 Hz); bCA; UV
irradiation followed the addition of bCA or UV irradiation followed the addition of BSA.
The sizes of each solution were recorded overtime by a Malvern Nanozetasizer ZS90 with
a 637-nm laser source with non-invasive backscattering technology detected at 173o using
disposable sizing cuvette. Standard operating procedures (SOP) are set up including
following parameters: the sample was equilibrated for 120 s at 25 oC before each
measurement; the sizes were reported as the hydrodynamic diameter (DH) and each
measurement average 16 runs were repeated three times; the data was automatically
analyzed by the zetasizer software through Mie model which then give the view of count
rate, correlation function, intensity particle size distribution (PSD), volume PSD and
Number PSD after each measurement.
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Transmission Electron Microscope (TEM) Study: The same sample for DLS measurement
was dropped onto carbon-coated copper grid. The grid was dried by slow evaporation in
air, and then dry separately in a vacuum overnight. Images were recorded on a JEOL2000FX electron microscopy operated at 200 kV and at a nominal magnification of 5000X.
At least 10 locations on the TEM grid were examined. The assembly diameter was
calculated using ImageJ software.
Atomic force microscopy (AFM): AFM images were taken using a Brucker Dimensions
3000 Scanning Probe Microscope under tapping mode. Silicon wafers [Cemat Silicon S.A.,
(111)-oriented] were pre-cleaned by sonication in ethanol and acetone for 20 min,
respectively. Then the wafers were dried with Ar flow and treated with UV-O3 for 15 min.
For AFM measurement, the oligomers at a concentration of 50 μM was drop-cast onto the
corresponding substrate.
DiI encapsulation: 50 μM oligomeric amphiphile solutions in PBS buffer were stirred at
room temperature and DiI stock solution (1 mg/mL in acetone, 5 wt% to 3, 4 or 5) was
added in each solution. The solutions were stirred for 8 h in room temperature, open to the
atmosphere allowing the organic solvent to evaporate, and then filtered through hydrophilic
membranes with pore size of 0.45 μm to remove unencapsulated DiI.
Guest release study: DiI-encapsulated oligomeric amphiphile solutions (50 μM) were
treated with 15 min UV irradiation; 60 μM bCA; 15 min UV irradiation followed the
addition of 60 μM bCA or 15 min UV irradiation followed the addition of 60 μM BSA.
The absorption spectra of DiI were recorded overtime. The % release of DiI was calculated
by using the following equations:
% Release of DiI = (It-I0)/It*100
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I0 =the highest absorbance of DiI; It = the highest absorbance of DiI at each time point
Calculation of critical aggregation concentration (CAC): A stock solution (1 mM) of 3/4/5
micelle was prepared was diluted into various solutions of different concentrations. The
concentration range of polymer was maintained from 0.1 mM to 0.001 mM. Nile Red was
encapsulated to the micelle by adding 10 μL of Nile Red stock solution (20 μM in acetone).
All the micelle solutions were kept uncapped overnight to evaporate the acetone. Then
emission spectrum was recorded for each solution and emission maxima of each spectrum
were plotted as a function of the concentration of 3/4/5. The inflection point of the plot was
taken as CAC of polymer 3/4/5.
2.4.2 Synthesis and characterization
Scheme 2.2. Synthetic protocol of masked ligand
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Synthesis of compound 1: 4-(Chlorosulfonyl) benzoic acid (2.2 g, 10 mmol) was taken into
a round bottomed flask along with 2-Nitrobenzylamine hydrochloride (1.89 g, 10 mmol)
and dissolved in the co-solvent of acetone (100 mL) and H2O (25 mL). NaHCO3 (1.68 g,
20 mmol) in H2O was then added to the reaction mixture. The solution was stirred for
overnight, concentrated, followed with the addition of 100 mL H2O. The residue was
extracted with 3×200 mL ethyl acetate, the organic phase was combined, concentrated and
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purified by combiflash using DCM/methanol as eluant. The product was eluted at a polarity
of 11% methanol in DCM and obtained as a light yellow solid. Yield: 27%. 1H NMR (400
MHz, DMSO-d6, TMS): δ (ppm) = 8.49 (t, 1H), 8.08 (d, 2H), 7.97 (d, 1H), 7.69 (t, 1H),
7.63 (d, 1H), 7.52 (t, 1H), 4.36 (d, 2H).
Synthesis of compound 6: Compound 1 (268 mg, 0.8 mmol) and N-Hydroxysuccinimide
(138 mg, 0.96 mmol) were dissolved in DMF (15 mL), followed with the addition of
EDC·HCl (184 mg, 1.2 mmol). The solution was allowed to stir in room temperature for
overnight. The reaction mixture was mixed with 50 mL DCM and washed with 3×30 mL
H2O, 3×30 mL saturated NaHCO3 solution and 3×30 mL brine. The organic layer was
collected and dried over anhydrous Na2SO4, concentrated and purified by combiflash using
hexanes/ethyl acetate as eluant. The product was eluted at polarity of 50% ethyl acetate in
hexanes and obtained as a light yellow solid. Yield: 88%. 1H NMR (400 MHz, CDCl3,
TMS): δ (ppm) = 8.19 (d, 2H), 8.00 (d, 1H), 7.91 (d, 2H), 7.56 (m, 2H), 7.44 (t, 1H), 4.48
(d, 2H), 2.93 (s, 4H).
Synthesis of compound 7: Compound 2 (260 mg, 0.6 mmol) and triethylamine (112
μL，0.8 mmol) were dissolved in 10 mL DCM and stirred. O-(2-Aminoethyl)-O’-(2azidoethyl) pentaethylene glycol (175 mg, 0.5 mmol) was dissolved in 5 mL DCM and
added to the reaction mixture dropwise with the help of an addition funnel. The reaction
was allowed to go on for overnight at room temperature, after which it was washed with
2×10 mL H2O and 2×10 mL brine. The DCM layer was then dried over Na2SO4,
concentrated and purified by combiflash using hexanes/ethyl acetate as eluant. The
product was eluted at a polarity of 100% ethyl acetate and obtained as amber liquid. Yield:
78%.1H NMR (400 MHz, CDCl3, TMS): δ (ppm) = 7.98 (d, 1H), 7.92 (d, 2H), 7.87 (d,
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2H), 7.60 (d, 2H), 7.47 (m, 1H), 7.15 (s, 1H), 5.66 (t, 1H), 4.44 (d, 2H), 3.70-3.59 (m,
26H), 3.36 (m, 2H).
General procedure for click reaction： The mixture of dendritic acetylene compound (1.0
eq), azide (2 eq for 1 acetylene group), CuSO4.5H2O (0.5 equiv.) and sodium ascorbate
(0.5 eq.) in THF/H2O (1:1) solvent mixture was heated at 50 oC for 24 h. The reaction
progress was monitored by TLC. After completion of the reaction, the reaction mixture
was partitioned between ethyl acetate and saturated aqueous NH4Cl solution. The aqueous
layer was extracted twice with ethyl acetate and the combined organic layer was dried over
Na2SO4 and evaporated to dryness. The crude product was purified by silica gel column
chromatography.
Synthesis of 3: Synthetic protocol of 3 is outlined in scheme 2.3.
Scheme 2.3. Synthetic protocol of targeted oligomer 3
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Synthesis of D1 (compound 5): Compound 8 was synthesized according to our previous
report1. According to general procedure for click reaction, compound 8 (50 mg, 35 μmol)
was treated with azide 7 (47 mg, 70 μmol) to give 52 mg of 3. Yield: 72%. NMR (400
MHz, CDCl3) δ 7.96 (t, 3H), 7.82 (d, 2H), 7.71 (br, 1H), 7.59 (d, 2H), 7.54 (m, 1H), 7.40
(t, 1H), 6.32 (s, 1H), 6.61 (m, 8H), 6.39 (t, 1H), 6.17 (t, 1H), 5.15 (s, 2H), 4.89 (s, 4H),
4.66 (s, 2H), 4.41 (m, 4H), 4.09 (t, 4H), 3.90-3.36 (m, 68H), 3.36 (s, 6H), 1.76-1.18 (m,
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NO2

48H), 0.95-0.80 (m, 9H); 13C NMR (400 MHz, CDCl3) δ 166.0, 160.4, 160.0, 159.0, 157.2,
156.3, 147.9, 142.6, 142.4, 139.4, 138.4, 135.8, 134.0, 132.5, 131.6, 128.9, 128.2, 126.9,
125.0, 119.3, 110.3, 106.2, 105.8, 104.8, 104.7, 100.9, 100.7, 71.9, 70.7, 70.6, 70.5, 70.5,
70.4, 70.4, 70.3, 69.7, 67.9, 67.4, 65.0, 59.0, 53.4, 50.3, 44.8, 40.1, 31.9, 29.7, 29.6, 29.5,
29.4, 29.3, 29.3, 29.3, 26.1, 26.0, 25.6, 22.7, 22.4, 14.1; ESI-TOF m/z 1067.4 [M+2Na]2+:
Calculated: 1067.32, found: 1067.4 [M]++Na: Calculated: 2111.64, found: 2112.0.
Synthesis of D2: Synthetic protocol of 5 is outlined in scheme 2.4:
Scheme 2.4. Synthetic protocol of targeted dendrimer D2
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and

4-

carboxybenzenesulfonamide (287 mg, 1.4 mmol) and HOBt (262 mg, 1.68 mmol)
in dimethylformamide (5 ml) and stirred for 24 hours at room temperature under nitrogen.
The solvent was removed in vacuo and the residue purified by column chromatography on
silica gel eluting with dichloromethane:methanol (95:5) (by volume) to give compound 11
as a colorless oil. Yield 87%. 1H NMR (CDCl3, 400 MHz) δ 7.77-7.84 (m, 4H), 7.56 (s,
1H), 6.24 (s, 1H), 3.36-3.73 (m, 24H). ESI-MS m/z calcd for [M+Na]+: 556.21; found:
556.3718.
Synthesis of compound 13: Compound 12 was prepared following our previously reported
procedure1. According to general procedure for click reaction, compound 12 (400 mg, 0.94
mmol) was treated with azide 11 (600 mg, 1.18 mmol) to give 560 mg of 13. Yield: 63%.
1

H NMR (CDCl3, 400 MHz) δ 7.91 (br s, 1H), 7.77 (m, 4H), 7.56 (s, 1H), 6.7 (s, 1H), 6.58

(s, 1H), 6.30 (m, 3H), 6.10 (br s, 1H), 4.64 (s, 2H), 4.53 (s, 2H), 4.46 (t, 2H), 4.21 (s, 4H),
3.93 (m, 4H), 3.78-3.83 (m, 6H), 3.52-3.73 (m, 50H), 3.35 (s, 6H), 1.55 (m, 2H), 1.2-1.4
(m, 14H), 0.88(m, 3H). ESI-MS m/z calcd for [M+Na]+: 959.45; found: 982.4715.
Synthesis of compound 14: Compound 10 (280 mg, 0.29 mmol), K2CO3 (121 mg, 0.87
mmol), 18-crown-6 (38 mg, 0.145 mmol) and compound 9 (305 mg, 0.638 mmol) were
mixed together in anhydrous acetone (50 mL) and refluxed for 12 h under argon. After
slowly cooling the reaction to room temperature and evaporating the solvent, the resultant
mixture was dissolved in ethyl acetate and washed with water. The combined organic
layers were dried over Na2SO4, concentrated under reduced pressure and the crude mixture
was purified by silica gel chromatography with MeOH/ethyl acetate (6:94 v/v) to give
compound 14 (135 mg, 27%). 1H NMR (CDCl3, 400 MHz) δ 7.94 (d, 2H), 7.79 (d, 2H),
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7.56 (br s, 1H), 7.53 (s, 1H), 6.72 (s, 1H), 6.63 (s, 1H), 6.17~6.39 (m, 9H), 5.08 (s, 2H),
4.64 (s, 2H), 4.53 (s, 2H), 4.46 (t, 2H), 4.21 (s, 4H), 3.93 (m, 4H), 3.78-3.83 (m, 6H), 3.523.73 (m, 50H), 3.35 (s, 6H), 1.55 (m, 2H), 1.2-1.4 (m, 14H), 0.88(m, 3H). ESI-MS m/z
calcd for C89H129N5O28SNa [M+Na] : 1770.85; found: 1771.5027, [M+2Na]2+ 896.7148.
Synthesis of 5：According to general procedure for click reaction, compound 14 (100 mg,
56 μmol) was treated with azide 10 (66 mg, 168 μmol) to give 66 mg of 5. Yield: 46%. 1H
NMR (CDCl3, 400 MHz) δ 8.15 (d, 2H), 7.94 (d, 2H), 7.89 (s, 2H), 7.79 (d, 2H), 7.53 (s,
1H), 7.48 (br s, 1H), 6.94 (m, 4H), 6.72 (s, 1H), 6.62 (s, 1H), 6.17~6.37 (m, 9H), 5.60 (s,
4H), 5.48 (s, 4H), 5.02 (d, 6H), 4.63 (s, 2H), 4.4 (t, 2H), 4.15 (s, 4H), 4.02 (t, 6H), 3.91 (m,
4H), 3.81 (m, 8H), 3.51-3.7 (m, 50H), 3.35 (s, 6H), 1.8 (m, 4H), 1.55 (m, 2H), 1.46 (m,
4H), 1.2-1.5 (m, 38H), 0.88 (m, 9H); 13C NMR ( CDCl3, 100 MHz) δ 166.2, 165.95, 163.70,
159.97, 159.15,157.16, 156.75, 156.35, 144.49, 144.10, 142.8, 139.82, 138.27, 137.91,
136.06, 133.82, 128.37, 128.18, 127.08, 125.00, 124.05, 119.64, 114.67, 113.76, 110.49,
107.54, 107.37, 104.95, 104.86, 101.77, 101.31, 71.89, 70.68, 70.54, 70.45, 70.38, 70.30,
70.04, 69.79, 69.56, 69.30, 69.15, 68.79, 67.42, 65.06, 64.92, 63.57, 61.64, 58.99, 55.99,
53.44, 51.25, 50.77, 50.18, 40.09, 31.89, 29.70, 29.59, 29.35, 29.31, 29.09, 28.98, 25.93,
22.68, 14.13. ESI-MS m/z calcd for C127H185N13O38SNa [M+Na]+: 2555.26; found:
2555.9831.
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CHAPTER 3
TUNABLE ENZYME RESPONSES IN AMPHIPHILIC NANOASSEMBLIES
THROUGH ALTERATIONS IN UNIMER-AGGREGATE EQUILIBRIUM
Adapted with permission from Gao, J.; Wang, Hui.; Zhuang, J.; Thayumanavan, S. Tunable
enzyme responses in amphiphilic nanoassemblies through alterations in unimer-aggregate
equilibrium. Chem. Sci., 2019, 10, 3018-3024. © The Royal Society of Chemistry 2019.
3.1 Introduction
Enzymes, as one of the most essential macromolecules in living organisms, are known
to catalyse more than 5000 biochemical reactions efficiently and serve a variety of
functions in biological processes.

[1]

Therefore, dysregulation of enzymatic activities has

been associated with many human pathologies. [2-4] In this context, introducing enzymes as
stimuli to trigger specific responses in artificial supramolecular assemblies have been of
interest, as these have potential in areas such as activity profile based biological imaging
and drug delivery. [5-13] A promising design strategy that leads to such materials involves
covalent incorporation of substrate functionalities in self-assembling molecules, such as
amphiphilic macromolecules, where the specific catalytic actions of an enzyme covalently
modify the substrate moiety. If it were to be designed such that the product of this
enzymatic reaction exhibits distinctly different self-assembly features, compared to the
substrate, then there exists a unique opportunity for programmable changes in the
nanostructures and their host-guest properties.
Many supramolecular systems including polymeric nanoparticles, hydrogels, silica
nanoparticles and gold nanoparticles have displayed adaptive behaviors toward enzymes.
[14-23]

Tunability in kinetics of the enzymatic response still remains a challenge, as it is
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mainly influenced by two factors: accessibility of enzyme to substrate moiety and degree
of difference in the host-guest properties between the reactant and product assemblies. In
the case of amphiphilic assemblies, our group and others have shown that enzymatic
activation usually occurs at unimeric state, where substrate is more accessible to enzyme
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Figure 3.1 Schematic representation of enzyme-induced disassembly and guest release
from varied oligomeric assemblies.
than their assembled micellar form.24,25 Following these findings, we have been interested
in investigating how the reaction kinetics and the ensuing change in the host-guest
characteristics would be affected by tuning unimer-aggregate equilibrium to alter the
assemblies’ accessibility to the enzyme. Moreover, we were interested in identifying as to
how structural changes in host assemblies, induced by an enzyme, would affect rate of
disassembly and kinetics of guest molecule release. We envisaged that oligomeric
amphiphiles would be an ideal choice to address this question, because: (i) these molecules
have critical aggregation concentrations (CACs) that are quite low and compare very well
with amphiphilic polymers; (ii) despite the fact that they do exhibit a low CAC, unlike
polymers, these are amenable to a well-defined structure−property relationship study as the
degree of oligomerization can be precise. Here we report a new modular design of
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oligomeric amphiphiles with which a precise control over degree of polymerization (DP)
and functional group placements in the scaffolds can be achieved (Figure 3.1). These
oligomers are expected to self-assemble in aqueous phase and host hydrophobic guests at
their interiors. By varying the DP and hydrophilic moieties of host molecules, we explore
the molecular features that underlie the kinetics of enzymatic response in these
supramolecular assemblies.
3.2 Results and discussion
3.2.1 Oligomer design and synthesis
Since enzymatic activation usually occurs at the unimeric state, where the substrate is
more accessible to enzyme than their assembled micellar form, we envisaged that shifting
the equilibrium between the unimer and the assembled state would provide an opportunity
to alter the enzymatic reaction rate. Degree of polymerization is one of the key factors that
can alter this equilibrium26-29 and thus change the accessibility of an enzyme to its substrate.
To test this possibility, it is critical that all the designed amphiphiles possess the same
hydrophilic-lipophilic balance (HLB). For this purpose, a series of oligomeric amphiphiles
from dimer (2-EG5) to pentamer (5-EG5), have been synthesized (Scheme 3.1). To further
evaluate the effects of DP on the enzymatic response, a polymer P-EG5 with ~14 repeating
units was also synthesized. In these amphiphiles, penta-ethylene glycol (EG5) monomethyl
ether moieties are installed as the hydrophilic functionality, while alkylated coumarin
moieties are used as the hydrophobic units. Both these units are attached to the metapositions of a benzoyl building block, which are then attached to well-defined oligoamines
to generate amphiphiles with different degrees of oligomerization. In all these systems, the
coumarin moiety is chosen as the covalently-appended model guest molecule. In order to
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release this guest molecule in the presence of an enzyme, we use an acetal-ester linkage to
connect the coumarin to the oligomer. The esterase-induced cleavage of the carboxylate
moiety would create a hemi-acetal coumarin, which is hydrolytically unstable. This hemiacetal therefore rapidly hydrolyzes further to generate a highly fluorescent, 4methylumbelliferone. In addition to releasing this covalently attached molecule, this
transformation

also

replaces

an

aryl

moiety

on

the

hydrophobic

side

of these amphiphiles with a carboxylic acid moiety. This change results in a significant
Scheme 3.1. Molecular structures of oligomers: legends of each oligomer indicate
increased degree of polymerization from 2-EG5 to P-EG5, EG5 indicates oligomers with
five ethyleneglycol units, EG8 indicates oligomers with eight ethyleneglycol units as
hydrophilic moiety.

Hydrophilicity

Degree of polymerizaiton (DP)

Scheme 3.2. Synthesis route of oligomers exemplified using 3-EG5
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change in the HLB of the amphiphile. Note that this series of amphiphiles share all the
common structural features including backbone, hydrophobic and hydrophilic
functionalities; the only variation within this series of amphiphiles is DP. Therefore, this
investigation allows us to inquire about the impact of this DP upon self-assembly and
enzyme induced disassembly events.
In addition to DP, HLB of oligomers is another factor that impact the unimer-aggregate
equilibrium. To test this possibility, with the same oligomer series above, we simply
increased the length of the oligoethyleneglycol chain length from five to eight units. Thus,
we synthesized four more oligomers 2-EG8, 3- EG8, 4- EG8, and 5- EG8 (Scheme 3.1).
We hypothesized that the increase in hydrophilicity upon going from penta-ethylene glycol
monomethyl ether (EG5) to octa-ethylene glycol (EG8) monomethyl ether would increase
the dynamics of the unimer-aggregate equilibrium, which will then increase the availability
of the substrate moiety for the enzymes. In this study, we also test this hypothesis.
The amphiphilic oligomers were designed in such a way that they can be synthesized in
a modular fashion, providing facile access to vary the number of repeating units and
functional group placement. The synthetic routes for the target oligomers are exemplified
by the synthesis of trimer 3-EG5 in Scheme 3.2. The 3,5-disubstituted-benzoyl chloride
molecule 1a was reacted with N,N”-dimethyl diethylenetriamine under basic conditions
to generate the substituted oligoamine scaffold 1b. This molecule now contains the
pentaethyleneglycol hydrophilic unit and the alkyne moiety to anchor the hydrophobic unit.
The hydrophobic and fluorogenic enzyme substrate was then attached at all three repeat
units of the oligomer using the Huisgen 1,3-dipolar cycloaddition reaction, the so-called
“click” chemistry14, to yield the desired oligomer 3-EG5 (Scheme 3.2).
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3.2.2 Nanoassembly preparation and characterization
We first investigated whether these oligomeric amphiphiles would form aggregates in
aqueous phase, since they contain both hydrophobic and hydrophilic moieties. If selfassembly occurs, the interior of these assemblies would have the capability to noncovalently encapsulate hydrophobic molecules. To test this, the oligomers were directly
dissolved in phosphate buffer and non-covalent incorporation of a solvatochromic dye,
Nile Red, within these assemblies was attempted. We found that at lower concentrations
of oligomers, the emission intensity of Nile Red was quite low. However, once the
concentration of the oligomers reached a certain point, a rather sharp increase in emission
intensity was observed. This onset point is taken to be the onset of hydrophobicity-driven
aggregation, which is estimated to be the critical aggregation concentration (CAC) of these
oligomers. As shown in Table 2.1, with DP increasing from 1 to 13, the CAC values of
these oligomers vary from 75 μM to 0.58 μM (Figure 3.2). In general, oligomers with
higher DP tend to aggregate at lower concentrations, despite the fact that the HLB of all
Table 3.1. Summary of oligomer assembly characterizations including critical aggregation
concentration and assembly size.
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these oligomers are identical. At same DP, the systems with longer ethylene glycol chains
as hydrophilic moiety exhibited higher CAC values.
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Figure 3.2 Critical aggregation concentration (CAC) of oligomeric assemblies.
a) 2-EG5

e) 2-EG8

c) 4-EG5

b) 3-EG5

f) 3-EG8

g) 4-EG8

d) 5-EG5

h) 5-EG8

1 um

Figure 3.3 TEM images of oligomeric assemblies.
The solution phase sizes of these nanoassemblies were then measured by dynamic light
scattering (DLS) at a concentration above their CACs. We observed an average
hydrodynamic diameter ranging from ~100-300 nm for these assemblies (Table 3.1). The
spherical morphology and size of these assemblies were further ascertained using
transmission electron microscopy (TEM), as shown in Figure 3.3.
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3.2.3 Covalently attached guest molecule release in presence of enzyme
Note that we hypothesized that if the HLB of the oligomers were kept constant, then
higher DP oligomeric amphiphiles would be hydrolyzed by enzyme at a slower rate than
their lower DP counterparts. To test this, we first measured the enzymatic cleavage rates
of all oligomers. Since the enzymatic reaction releases the fluorescent byproduct, 4methylumbelliferone, we were able to monitor the cleavage rates spectroscopically. For an
accurate comparison, it is necessary that all these oligomer solutions are not only prepared
at concentrations above their respective CACs, but also contain the same concentration of
the substrate functionalities, regardless of their DP. To meet these two criteria, we prepared
oligomer solutions that contain 200 μM enzyme substrates (based on coumarin), i.e. 100
μM dimer, 66.7 μM trimer, 50 μM tetramer, and 40 μM pentamer, and then treated with 60
nM esterase. As shown in Figure 3.4, a clear trend of the enzymatic reaction rate was
observed for these oligomers with PEG as hydrophilic moieties, amphiphile 2-EG5
exhibited the fastest enzymatic rate over 48 hours, systematically followed by 3-EG5, 4EG5 and 5- EG5. Moreover, when the same concentrations of enzyme and the substrate
were used in the case of the 14-mer P-EG5, the molecular weight of which is comparable
to polymers, little hydrolysis was observed from the emission spectra. These results are
consistent with our hypothesis that the higher DP would result in slower enzymatic reaction
rate, which in turn provides a convenient handle to tune reaction rates of enzymes and the
resultant release of the covalently bound molecules.
When same experiments were performed with the second series of oligomers (the EG8
series) that contain longer ethylene glycol chains as the hydrophilic group, a similar trend
was indeed observed, i.e. hydrolysis rate decreases for oligomers with higher DP. These
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Figure 3.4. Enzymatic hydrolysis of oligomeric assemblies based on coumarin release a)
oligomer assemblies with EG5 as hydrophilic moiety, b) oligomer assemblies with EG8 as
hydrophilic moiety, enzymatic hydrolysis comparison between oligomer-EG5 and
corresponding oligomer-EG8 c) - f).
results again confirmed our hypothesis that amphiphiles with higher DP are less accessible
to enzyme and thus more stable compared with oligomers with lower DP. Meanwhile,
comparison of the two series of oligomers also allows us to evaluate HLB effects on the
enzymatic hydrolysis rates of these oligomers. Note that the basis for our hypothesis that
the degree of oligomerization would causes slower reaction rate is that the dynamics of the
unimer-aggregate equilibrium would be slower at higher DP. The results above support
this hypothesis. If this were true, then it should also follow that if the hydrophilicity of
these oligomers changes, the dynamics of the unimer-aggregate equilibrium would also be
affected, which would in turn alter the sensitivity of these oligomers to enzyme. To test
this idea, we compared the hydrolysis rates of EG5 oligomers and EG8 oligomers under
the same experimental conditions. Interestingly, we observed that the cleavage rate of the
covalently attached molecules from 2-EG5 and 2-EG8 were very similar (Figure 3.4c).
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However, when the DP increases to trimeric or higher, n-EG8 oligomers with longer
ethylene glycol chains indeed consistently exhibited faster cleavage, compared to their
corresponding n-EG5 oligomers with shorter PEG chains (Figure 3.4d-f). These results
suggest that lowering hydrophilicity of oligomers will make them more stable in presence
of esterase. This is reasonably expected, because increase in hydrophilicity is expected to
increase the dynamics in the unimer-aggregate equilibrium, which facilitates enzyme’s
access to its substrate functionalities. We attribute the lack of significant difference
between 2-EG5 and 2-EG8 assemblies to the fact that these low order oligomers are
already sufficiently dynamic, such that there is no significant advantage to increasing the
hydrophilicity of the oligomeric amphiphile from EG5 to EG8.
3.2.4 Non-covalent guest molecule release in presence of enzyme
Next, we were interested in evaluating the effect of the enzyme-induced change in the
HLB of the amphiphiles upon their host characteristics for hydrohobic guest molecules.
We were especially interested in identifying whether this anticipated molecular release
event will follow a DP- and hydrophilicity- dependent trend observed in the covalent
modification of the amphiphile. To test these, we encapsulated a hydrophobic fluorophore,
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (DiI), into these assemblies. The
DiI-encapsulated oligomeric assemblies were treated with the esterase and the molecular
release was assessed by fluorescence change. A change in fluorescence is anticipated in
this case, because DiI molecule is insoluble in aqueous solutions and therefore precipitates
out of solution, upon release from the hydrophobic pockets of these amphiphilic assemblies.
As with the experiments above, the concentration of esterase and the substrate
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functionalities in the oligomers were maintained for appropriate comparison of the relative
rates of molecular release.
Indeed, we found that the guest release depends on the DP of oligomers at constant HLB
of the molecule, i.e. within the same oligomer series (EG5 or EG8 series). That is,
assemblies from higher order oligomers exhibit the ability to more stably encapsulate the
guest molecules and responds to the enzyme much more slowly, compared to the lower
order oligomers (Figure 3.5). Also, assemblies with longer ethylene glycol chains can
release guest molecules much faster at the same time range (Figure 3.5, 3.6). These results
show that a precise control over the release kinetics of non-covalently encapsulated guest
molecules can also be achieved by tuning the molecular structures.
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Figure 3.5. Non-covalent guest (DiI) release from nanoassemblies.
Comparison of data for the covalent molecular release based on the enzymatic cleavage
of the substrate functionalities and the release of the non-covalently bound guest molecules
revealed that the latter process lags behind the former process. The potential reason behind
this difference is that the enzymatic cleavage of the covalently attached guest molecules
happens first, which is followed by the loss in capability of the amphiphilic assemblies to
hold the guest molecules to cause molecular release. In this scenario, the intermediate states
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of the aggregated assemblies generated by the enzymatic reaction (e.g. only one of the
coumarin moieties cleaved in a pentameric amphiphile) also can bind to guest molecules,
but their relative ability to act as a host might be lower. This process in conjunction with
the need for a critical concentration of DiI to cause its precipitation likely manifests itself
as the lag in the non-covalent guest release, relative to the covalent modification of the
oligomers by the enzyme.
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Figure 3.6. Comparison of non-covalent guest release kinetics between oligomer-PEG and
oligomer-OEG.
3.2.5 Assembly size transformation in response to enzyme
Since the enzymatic cleavage of hydrophobic groups seems to be the primary reason for
assemblies to lose their stability and capability to hold guest molecules, it is likely that this
enzyme reaction induces morphological changes of the aggregated assemblies. To test this
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Figure 3.7. Size evolution of assemblies in presence of esterase in 48 hours.
possibility, we monitored the temporal evolution of the size of these assemblies by DLS.
We found that the size of assemblies change immediately after esterase was introduced to
these systems. As shown in Figure 3.7, both 2-EG5 and 3-EG5 completely disassembled
in presence of enzyme: the size of assembly 2-EG5 sharply decreased from ~240 nm to
~20 nm, while assembly 3-EG5 formed a ~35 nm assembly from an initial size of ~220
nm in 48 hours, this size change was also confirmed by TEM images which showed clear
spherical structures initially but little visible aggregates after 48 hours of enzymatic
reactions. However, the size of oligomers 4-EG5 and 5-EG5 remained relatively
unchanged over the same timeframe. Furthermore, a similar trend of assembly size change
was observed for n-EG8 oligomers with longer EG chains at same experimental conditions.
While 4-EG8 and 5-EG8 were rather more stable in presence of enzyme, both 2-EG8 and
3-EG8 completely disassembled in presence of enzyme at a faster rate compared with
corresponding n-EG5 oligomers, respectively. These results suggested that enzymatic
cleavage can induce the disassembly process. Also, both DP and HLB variations of
oligomeric amphiphiles can alter the disassembly kinetics, which correlate well with the
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guest release profiles of both covalently bound and non-covalently bound hydrophobic
molecules.
3.3 Summary
To summarize, two series of oligomeric amphiphiles were prepared to evaluate the
possibility of tuning enzyme-induced changes in their self-assembly properties and hostguest characteristics. We have shown that: (i) when the degree of oligomerization increases
in the amphiphiles, the enzymatic reaction rate decreases. This offers a straightforward
opportunity to tune the release kinetics of covalently-appended guest molecules. (ii) This
reaction kinetics can also be tuned by varying the hydrophilic-lipophilic balance of the selfassembling substrate molecule itself, where increase hydrophilicity accelerates the
molecular release rates. (iii) In the assemblies where the enzyme-induced alteration in HLB
occurs at a reasonable rate, i.e. in lower order oligomers, a significant change in size and
morphology of the assemblies were also observed. (iv) Non-covalently bound guest
molecules can also be released from these amphiphilic assemblies in response to the
enzyme-induced alteration in HLB, the trends of which closely follows those observed in
the release of the covalently bound guest molecules. The trends in the enzymatic reaction
rates and the change in the host-guest characteristics can be understood by correlating
structural variations to change in the dynamics of unimer-aggregate equilibrium. Factors
that lead to faster unimer-aggregate equilibrium dynamics lead to faster enzymatic
response. Overall, this study provides two simple and straightforward approaches to
altering enzyme-induced changes in amphiphilic assemblies, which in turn offer tunability
in the release kinetics of covalently and non-covalently bound guest molecules from these
assemblies. The findings presented here could provide a basis for designing enzyme
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responsive materials with controlled release capabilities in materials and biomedical
applications.
3.4 Experimental procedures
3.4.1 General Methods
All the reagents were from commercial source and used as received. 1H NMR and

13

C

NMR spectra were recorded on a Bruker DPX-400 MHz NMR spectrometer using the
residual proton resonance of the solvent as the internal standard. All molecules without
characterization data mentioned below were synthesized through well-established
synthesis procedures previously reported by our group.30-32 UV-vis absorption spectra were
obtained by a Carry 100 Scan spectrometer. Fluorescence spectra were recorded on a
PerkinElmer LS 55 spectrofluorimeter. Mass spectrometric data were collected by
Capillary LC (Thermo Dionex Ultimate 3000)-ESI-MS (Bruker AmaZon quadrupole ion
trap).
For the DLS measurements, the sizes of each solution were recorded overtime by a Malvern
Nanozetasizer ZS90 with a 637-nm laser source with non-invasive backscattering
technology detected at 173o using disposable sizing cuvette.
The same sample for DLS measurement was dropped onto carbon-coated copper grid. The
grid was dried by slow evaporation in air, and then dry separately in a vacuum overnight.
Images were recorded on a JEOL-2000FX electron microscopy operated at 200 kV and at
a nominal magnification of 5000X. At least 10 locations on the TEM grid were examined.
A stock solution (1 mM) of oligomer micelle was prepared was diluted into various
solutions of different concentrations. The concentration range of polymer was maintained
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from 0.2 mM to 0.001 mM. Nile Red was encapsulated to the micelle by adding 10 μL of
Nile Red stock solution (20 μM in acetone). All the micelle solutions were kept uncapped
overnight to evaporate the acetone. Then emission spectrum was recorded for each solution
and emission maxima of each spectrum were plotted as a function of the concentration of
each oligomer. The inflection point of the plot was taken as CAC of each oligomer.
For DiI encapsulation, oligomeric amphiphile solutions in phosphate buffer were stirred at
room temperature and DiI stock solution (1 mg/mL in acetone, 5 wt% to oligomers) was
added in each solution. The solutions were stirred for 8 h in room temperature, open to the
atmosphere allowing the organic solvent to evaporate, and then filtered through hydrophilic
membranes with pore size of 0.45 μm to remove unencapsulated DiI.
For guest release study, DiI-encapsulated oligomeric amphiphile solutions (50 μM) were
treated with esterase. The absorption spectra of DiI were recorded overtime.
The % release of DiI was calculated by using the following equations:
% Release of DiI = (It-I0)/It*100
Where I0 =the highest absorbance of DiI
It = the highest absorbance of DiI at each time point
3.4.2. Synthetic procedures
General procedures for synthesis of molecule b: Oligoamine (1 eq.) was dissolved in dry
tetrahydrofuran (THF), trienthylamine (2 eq. for 1 amine group) was added to the solution
and stirred for 15 minutes at 0oC. A solution of benzoyl chloride molecule 1a (1.2eq for
one amine group) in THF was added to the mixture dropwise and then stirred at room
temperature overnight. Solvent was evaporated and then redissolved in dichloromethane,
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then washed with water for three times. The organic layer was dried over Na2SO4 and
evaporated to dryness. The crude product was purified by silica gel column
chromatography.
General procedures for synthesis oligomers: The mixture of oligomeric acetylene
compound b (1.0 eq.), azide 1c (2 eq. for 1 acetylene group), CuSO4.5H2O (0.5 eq.) and
sodium ascorbate (0.5 eq.) in THF/H2O (1:1) solvent mixture was heated at 50 oC for 24 h.
The reaction progress was monitored by TLC. After completion of the reaction, the reaction
mixture was partitioned between ethyl acetate and saturated aqueous NH4Cl solution. The
aqueous layer was extracted twice with ethyl acetate and the combined organic layer was
dried over Na2SO4 and evaporated to dryness. The crude product was purified by silica gel
column chromatography.
3.4.3 Characterizations for oligomers
2-EG5: Yield: 94%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.63 (s, 2H), 7.55 (d, J =
8.8 Hz, 2H), 6.99-6.94 (m, 4H), 6.59-6.55 (m, 6H), 6.17 (s, 2H), 5.80 (s, 4H), 5.15 (s, 2H),
5.01 (s, 2H), 4.27 (t, J = 5 Hz, 4H), 4.01-3.54 (m, 40H), 3.36 (s, 6H), 3.05 (s, 4H), 2.412.35 (m,10H), 1.89 (m, 4H), 1.63 (m,8H), 1.33 (m, 4H). 13C NMR (100 MHz, CDCl3) δ
(ppm) 171.98, 171.36, 160.92, 159.43, 154.89, 152.37, 138.18, 125.92, 115.18, 113.18,
112.95, 105.89, 105.53, 103.38, 84.70, 71.91, 70.73, 70.56, 70.54, 70.48, 69.52, 67.63,
61.82, 59.01, 44.51, 37.92, 33.68, 29.79, 25.86, 23.90, 18.70. MALDI-ToF m/z 1618.593
(C80H106N8O26+Na+ requires 1617.738).
3-EG5: Yield: 90%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.69-7.64 (m, 3H), 7.55
(d, J = 8.8 Hz, 3H), 6.98-6.94 (m, 6H), 6.56-6.52 (m, 9H), 6.17 (s, 3H), 5.80 (s, 6H), 5.184.92 (m, 6H), 4.31-4.27 (m, 6H), 4.12-3.52 (m, 62H), 3.36 (s, 9H), 3.05-2.99 (d, J = 13.6
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Hz, 3H), 2.65 (s, 3H), 2.40-2.38 (m, 15H), 1.89 (m, 6H), 1.63 (m, 12H), 1.33 (m, 6H). 13C
NMR (100 MHz, CDCl3) δ (ppm) 171.97, 160.90, 160.03, 159.87, 159.40, 159.23, 154.84,
152.42, 137.67, 125.93, 115.15, 113.16, 112.88, 105.51, 103.34, 84.67, 71.86, 70.68, 70.50,
70.43, 69.47, 67.71, 61.91, 58.97, 50.33, 33.65, 29.74, 25.84, 23.87, 18.68. MALDI-ToF
m/z 2414.982 (C120H158N12O39+Na+ requires 2414.107).
4-EG5: Yield: 76%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.72 (m, 4H), 7.55 (d, J
= 4.4 Hz, 4H), 7.01-6.94 (m, 8H), 6.59-6.53 (m, 12H), 6.19 (s, 4H), 5.80 (s, 8H), 5.31-5.02
(m, 8H), 4.32 (m, 8H), 4.13-3.54 (m, 80H), 3.37 (s, 12H), 3.05 (m, 4H), 2.64 (m, 3H)2.422.39 (m,20H), 1.89 (m, 8H), 1.71 (m, 16H), 1.33 (m, 8H). 13C NMR (100 MHz, CDCl3) δ
(ppm) 171.99, 160.91, 159.86, 154.86, 152.41, 125.93, 115.16, 113.16, 112.90, 103.36,
103.17, 84.68, 71.88, 70.68, 70.59, 69.48, 67.59, 58.99, 50.07, 33.87, 29.80, 25.83, 23.89,
18.69. MALDI-ToF m/z 3211.185 (C160H210N16O52+Na+ requires 3210.476).
5-EG5: Yield: 78%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.73 (m, 5H), 7.53 (d, J
= 4.2 Hz, 5H), 6.97-6.94 (m, 10H), 6.52 (m, 15H), 6.16 (s, 5H), 5.80 (s, 10H), 5.29-4.95
(m, 10H), 4.29 (m, 10H), 4.13-3.54 (m, 128H), 3.37 (s, 15H), 2.96(m, 4H), 2.61 (m, 4H),
2.39-2.36 (m,25H), 1.89 (m, 10H), 1.68 (m, 20H), 1.34 (m, 10H). 13C NMR (100 MHz,
CDCl3) δ (ppm) 171.99, 160.90, 160.05, 159.42, 154.85, 152.42, 137.73, 125.96, 115.15,
113.16, 112.89, 105.85, 103.37, 84.75, 71.88, 70.50, 69.50, 67.72, 58.99, 33.68, 29.67,
25.99, 23.89, 18.71. MALDI-ToF m/z 4007.328 (C200H262N20O65+Na+ requires 4006.845).
P-EG5: Yield: 80%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.71, 7.53, 6.94, 6.45,
6.13, 5.78, 5.07, 4.91, 4.25, 3.60-3.33, 2.38, 1.83, 1.62, 1.31. 13C NMR (100 MHz, CDCl3)
δ (ppm) 172.02, 160.87, 159.98, 159.44, 154.83, 152.50, 137.69, 126.04, 115.12, 113.10,
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112.83, 105.15, 103.38, 84.71, 71.87, 70.46, 70.45, 62.32, 67.57, 58.97, 49.92, 33.66, 29.82,
25.83, 23.89, 18.69. THF GPC: Mw 12 kDa, PDI 1.08.
2-EG8: Yield: 92%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.63 (s, 2H), 7.54 (d, J =
4.4 Hz, 2H), 6.95 (m, 4H), 6.59-6.52 (m, 6H), 6.17 (s, 2H), 5.80 (s, 4H), 5.15 (s, 2H), 5.01
(s, 2H), 4.28 (t, J = 3.6 Hz, 4H), 4.11-3.53 (m, 60H), 3.36 (s, 6H), 3.05 (s, 3H), 2.71(s,
2H), 2.41-2.37 (m,10H), 1.89 (m, 4H), 1.69 (m, 8H), 1.33 (m, 4H).
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C NMR (100 MHz,

CDCl3) δ (ppm) 171.98, 160.92, 159.91, 159.42, 154.87, 152.39, 138.16, 125.92, 123.11,
115.17, 113.17, 112.92, 105.86, 105.51, 103.36, 103.21, 84.67, 71.90, 70.70, 70.52, 70.46,
69. 50, 67.60, 61.96, 59.01, 49.99, 33.67, 29.84, 29.68, 25.80, 23.89, 18.69. MALDI-ToF
m/z 1882. 356 (C92H130N8O32+Na+ requires 1881.879).
3-EG8: Yield:69%. 1H NMR (400 MHz, CDCl3, TMS):δ (ppm) 7.69-7.67 (m, 3H), 7.55
(d, J = 4.4 Hz, 3H), 6.98-6.95 (m, 6H), 6.56-6.51 (m, 9H), 6.17 (s, 3H), 5.80 (s, 6H), 5.184.92 (m, 6H), 4.29 (m, 6H), 4.12-3.52 (m, 98H), 3.36 (s, 9H), 3.05-2.99 (d, J = 13.2 Hz,
3H), 2.65 (s, 3H), 2.40-2.35 (m, 15H), 1.89 (m, 6H), 1.63 (m, 12H), 1.34 (m, 6H).13C NMR
(100 MHz, CDCl3) δ (ppm) 171.96, 160.90, 160.04, 159.40, 154.84, 152.41, 137.91,
125.93, 115.15, 113.16, 112.88, 105.86, 103.34, 84.67, 71.87, 70.68, 70.49, 69.48, 67.69,
61.86, 58.98, 50.23, 33.65, 29.76, 25.82, 23.87, 18.68. MALDI-ToF m/z 2810.593
(C138H194N12O48+Na+ requires 2810.342).
4-EG8: Yield: 77%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.69 (m, 4H), 7.53-7.51
(d, J = 4.2 Hz, 4H), 6.96-6.93 (m, 8H), 6.53-6.50 (m, 12H), 6.15 (s, 4H), 5.79 (s, 8H), 5.014.95 (m, 8H), 4.27 (m, 8H), 4.13-3.54 (m, 120H), 3.36 (s, 12H), 2.97 (s, 3H), 2.71-2.58 (m,
3H), 2.39-2.34 (m, 20H), 1.89 (m, 8H), 1.65 (m, 16H), 1.33 (m, 8H). 13C NMR (100 MHz,
CDCl3) δ (ppm) 172.07, 160.86, 160.05, 159.86, 154.85, 152.40, 137.67, 125.95, 115.14,
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113.14, 112.88, 105.48, 103.35, 84.69, 71.88, 70.68, 70.50, 69.50, 67.71, 59.00, 53.51,
46.06, 33.91, 29.66, 26.06, 25.88, 18.69. MALDI-ToF m/z 3738.234 (C184H258N16O64+Na+
requires 3738.788).
5-EG8: Yield: 82%. 1H NMR (400 MHz, CDCl3, TMS): δ (ppm) 7.73 (m, 5H), 7.55-7.53
(d, J = 4.2 Hz, 5H), 7.00-6.95 (m, 10H), 6.51 (m, 15H), 6.16 (s, 5H), 5.80 (s, 10H), 5.194.96 (m, 10H), 4.29 (m, 10H), 4.08-3.51 (m, 166H), 3.36 (s, 15H), 2.96(m, 3H), 2.61 (m,
3H), 2.40 (m,25H), 1.88 (m, 10H), 1.65 (m, 20H), 1.31 (m, 10H).

13

C NMR (100 MHz,

CDCl3) δ (ppm) 172.01, 160.92, 160.07, 159.44, 154.87, 152.43, 125.97, 115.17, 113.18,
112.91, 106.20, 103.39, 84.75, 71.90, 70.52, 69.52, 67.61, 59.02, 33.70, 29.69, 25.95, 23.91,
18.73. MALDI-ToF m/z 4667.821. (C230H322N20O80+Na+ requires 4667.235).
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CHAPTER 4
PERIPHERY FUNCTIONALIZABLE SELF-IMMOLATIVE NANOGEL FOR
TARGET DELIVERY INTO CYTOSOL AND SUBCELLULAR ORGANELLES
4.1 Introduction
Nanoparticles as drug delivery vehicles have displayed huge potential to combat the
implications that are always associated with traditional drug administration methods1-2,
such as fast clearance, poor solubility and off target effects. By delivering the exact dose
of therapeutic drugs to a specific disease site, nanoparticles could level up the therapeutic
efficiency and safety.3-6 To date, various materials include dendrimers, polymers, gold
nanoparticle, silica nanoparticle and liposome have been exploited towards either
improving cargo loading efficiency, targeting capability or controlling the drug release.7-14
Current challenges in this emerging field involve the design of nanoparticles displaying
multiple features, and in particular, converging all these merits into one simple platform
without compromising synthetic ease and attractive features. Self-immolative polymers
provided an opportunity for programmed fragmentation and triggered release from
peripheral functional groups, which could promote advanced drug delivery but require
extensive synthesis.15-20 Previously our group have introduced an emulsion-free method to
prepare crosslinked nanogels which can sequester hydrophobic guest molecules in aqueous
media and release them in response to a biologically relevant stimulus.21-23 However, the
post-functionalization through disulfide-exchange offers limited efficiency and could
induce loss of encapsulation stability due to the cleavage of hydrophobic functional groups.
We envisaged that a periphery functionalizable self-immolative nanogel platform would
be an ideal system for targeted drug delivery into cytosol or subcellular organelles (Figure
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4.1). The primary requirements for this platform to meet are: 1) ease of synthesis, 2) high
drug loading capacity, 3) fast triggerable release, 4) facile post-functionalization, 5)
targeting capability. We hypothesized that incorporation of cross-linkable hydrophobic
units in an amphiphilic polymer, with triggerable self-immolative feature, would generate
nanoassemblies with capabilities to hold guest molecules and release them in response to
an environmental stimulus. Meanwhile, introducing a reactive handle on the surface of
nanogels would provide easy access to install various ligands for targeted delivery.

Figure 4.1. Illustration of functionalized nanogel for targeted delivery into cytosol and
subcellular organelles.
4.2 Results and discussion
4.2.1 Molecular design and synthesis
To this end, an amphiphilic block copolymer P1 that satisfies all the above requirements
is synthesized through RAFT polymerization, which contains amine terminated
polyethyleneglycol (PEG5000) as the hydrophilic moiety and carbonate bridged pyridyl
disulfide (PDS) as the hydrophobic moiety (Scheme 4.1). Polymers with varied repeating
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units of PDS were synthesized for optimizaiton of drug loading (table 4.1). The key
premise of this molecular design here is that once this polymer self-assembles, it will
generate nanoparticles with a functionalizable surface with amine as the reactive handle,
and a hydrophobic core that is crosslinkable and responsive to highly reductive intracellular
environment. The cleavage of disulfide will further cleave the carbonate to make the
polymer completely hydrophilic, which will benefit the payload release.
Scheme 4.1 Functional nanogel preparation illustration (a) and reaction scheme for
polymer synthesis (b) and mechanism for redox triggered decrosslinking and selfimmolation.

Table 4.1 Characterization data of polymers synthesized
Mn

Mw

(kDa)

(kDa)

1:10

11.1

12.7

1.15

1:20

13.6

13.9

1.02

1:30

13.1

15

1.14

PEG:PDS Ratio
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4.2.2 Nanogel preparation and characterization
To test our design, polymer P1 was distributed in phosphate buffer (10 mM, pH 7.4),
nanoassemblies with a size ~105 nm was observed from dynamic light scattering (DLS)
shown in Figure 4.2a. Following this step, addition of dithiothreitol (DTT) would induce
the crosslinking of the nanoparticle core through cleavage of PDS groups and results in the
formation of nanogels, the crosslinking density can be quantitatively determined by the
pyridothione released. Size of the crosslinked nanogels is similar to the initial
nanoaggregates (Figure 4.2a), the spherical morphology was also confirmed by
transmission electron microscopy (TEM) as shown in Figure 4.2c. It is noteworthy that free
thiol generated after PDS cleavage could potentially trigger the polymer self-immolation,
which competes with the crosslinking reaction. After monitoring the crosslinking reaction
with varied amount of DTT using NMR, we figured out that self-immolation of the polymer
proceeded only when excess DTT (higher than 0.5 equivalence of PDS group) is present
a) 30

Micelles
Micelles + 0.1 eq DTT

b)

20

30

Intensity

Intensity

No DTT
0.25 eq DTT
0.5 eq DTT
1 eq DTT

40

10

20
10

0

0
1

10

100

1000

1

c)

10

100

1000

Size (d.nm)

Size (d.nm)

d)

e)

Figure 4.2. a) DLS profile of micelles before and after crosslinking by DTT, b) DLS profile
of micelles treated with varied amount of DTT, TEM images of nanogels treated with
varied amount of DTT c) 0.25 eq, d) 0.5 eq, e) 1eq, scale bar 100nm.
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(Figure 4.3). This is further confirmed by monitoring the size of these assemblies with
different concentration of DTT, as shown in figure 4.2b-e, deficient amount of DTT (less
than 0.5 eq. of PDS group) resulted in a crosslinked nanogel that is similar in size to the
micelles, while excess DTT would degrade the assemblies. The findings here equipped the
nanogel with interesting features such as proper size, crosslinkable core and triggerable
degradation.

Figure 4.3. NMR of micelle solution in presence of different amount of DTT, peak a and b
indicates the self-immolated polymer, which was only observed when excess amount of
DTT (more than 0.5 eq.)was added.
We anticipated the amine functional group located at the terminus of hydrophilic PEG
chain would present at the surface of the nanogel, which could provide free access to for
independent post functionalization. This possibility was tested by adding fluoresceinamine,
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an amine reactive fluorescent molecule, to the nanogel solution. Since fluoresceinamine
itself is non-fluorescent in buffer, the strong emission peak generated from the nanogel
solution suggested the successful covalent labeling reaction (Figure 4.4a). Surface zeta
potential change from positive to negative also confirmed this post-modification event
(Figure 4.4b).
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Figure 4.4 a) Emission spectrum of nanogel treated with fluoresceinamine, b) Zeta
potential of nanogel before and after reaction with fluoresceinamine, c) Absorption of
encapsulated DiI in nanogel for 1 day and 14 days, d) DiI release from the nanogel in
presence of 10 mM/10 uM GSH.
The capability of encapsulating guest molecules was firstly evaluated with 1,1'dioctadecyl-3,3,3'3'-tetramethyl-indocarbocyanine perchlorate (DiI). Encapsulation of DiI
achieved over 96% loading efficiency and was found to be extremely stable in the
crosslinked nanogel within two weeks, indicated by the characteristic absorption of DiI
(Figure 4.4c). We are then interested to see whether the trapped guest molecules can be
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released efficiently in response to a biologically relevant stimulus. We expected that
glutathione (GSH), with millimolar concentration level in cytosol, would cleave the
disulfide crosslinking and induce the release guest molecules. High concentration of GSH
will also facilitate the self-immolation of the carbonate bond and result in huge decrease of
the hydrophobicity of the nanogel, which could further promote the guest release. To test
this, we treated the dye-loaded nanogel solutions with different concentrations of GSH (10
μM and10 mM, correspond to extra- and intra-cellular level GSH concentrations) and
investigated their release profiles by tracing the decrease of the hydrophobic dye’s
absorption caused by its insolubility in aqueous media. The nanogel was able to hold most
of the guest molecules at low GSH concentration, but at high GSH concentration, 83% of
loaded cargo was released in 72 hours, which is much more efficient compare with previous
reported system (Figure 4.4d).21,24 Followed by these observations, two different
chemotherapy drugs, paclitaxel (PTX) and doxorubicin (DOX), were encapsulated in the
nanogel. By modifying the drug feeding ratio from 10 wt% to 30 wt%, crosslinking density
from 10% to 30% and hydrophobic repeating units of polymer from 10 to 20, 24.3 wt %
and 6.5 wt % loading capacity were achieved for PTX and DOX using polymer P1 with
20% crosslinking, respectively (Table 4.2).
Table 4.2. Optimization of drug loading capacity.
Variations
Trial #

Result: loading capacity

a. X-linking
10% 20% 30%

b. Drug feeding
10% 20% 30%

c. PEG:PDS ratio
1 10 1 20

Doxorubicin

1

a1

b1

c1

2.9 0.13%

6.3 0.1%

2

a1

b2

c1

4.8 0.08%

10.2 0.21%

3

a1

b3

c1

5.5 0.12%

22.3 0.13%

4

a1

b1

c2

3.1 0.05%

6.2 0.08%

5

a1

b2

c2

4.4 0.11%

13.7 0.13%

6

a1

b3

c2

4.9 0.09%

23.7 0.12%

7

a2

b3

c1

6.5 0.07%

24.3 0.15%

8

a3

b3

c1

5.1 0.14%

21.1 0.22%
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Paclitaxel

4.2.3 Cytosolic drug delivery
These nanogels themselves are nontoxic to cells such as 293T and MDA-MB-231 cells
even at high concentrations, which provides the opportunity to act as drug delivery system
(Figure 4.5). With these exciting features of this nanogel system, we are interested to
explore the capability of this nanogel to deliver chemotherapeutic drugs into cytosol or
even subcellular organelles in cancer cell lines. Folate receptors have been known to be
overexpressed in malignant tumors25-27, which hold potential for folate-based tumor
imaging and drug delivery.25,28 We envisaged that decoration the nanogel with folic acid
could enhance the nanogel uptake in folate positive cells (Figure 4.6a). To test this, folic
acid decorated nanogel (FA-Nanogel) was labeled with Cy3 dye to monitor cellular uptake
in folate positive breast cancer cell MDA-MB-231 and folate negative cell HepG2. After 3
hours incubation, significant red fluorescence was observed in MDA-MB-231 cells using
confocal laser scanning microscopy (CLSM), but limited fluorescence signal was found in
HepG 2 cells, indicating folic acid could enhance the uptake towards FR positive cells
(Figure 4.6b,c). Next, we evaluated cell viabilities of MDA-MB-231 cells with nanogels
using MTT assay. Empty nanogels were barely toxic even at high concentrations, but the
PTX loaded nanogel lower cell viabilities by 40% and FA-nanogel was found to be more
efficient to induce cell death, suggesting PTX has been delivered into the cells efficiently.

Figure 4.5. Cell viability of control nanogels at varied concentrations.
71

Notably, increasing the folic acid content on nanogel from 25% to 100% (molar ratio to
PEG chain) also resulted in a decrease in cell viability (Figure 4.6d).

Figure 4.6. Efficient cytosolic delivery into MDA-MB-231 cells using folic acid
functionalized nanogel. a) Functionalization of nanogel with Cy3 and folic acid, b) cellular
uptake of control nanogel (b) and folic acid functionalized nanogel (c) after 3 h incubation
(red, cy3-nanogel; blue, heochst). c) Cell viability of empty nanogel and PTX loaded
nanogel with varied folic acid content from 0 to 100% (eq. per PEG chain).
4.2.4 Targeted drug delivery into mitochondria
To test the versatility of our system, we were interested in the potential of this strategy for
subcellular organelle targeting. Mitochondria, as key regulators of cell apoptosis, necrosis
and autophagy, has been an attractive drug target.29-31 PTX has been shown to act on
mitochondria triggering apoptosis but normally only a fraction of drug molecules is
available to mitochondria due to multiple interactions with other cell compartments,32,33
the drug efficiency would be significantly improved if it can be specifically delivered into
the mitochondria. To this end, triphenyl phosphinium (TPP)31,34, a molecular motif

72

targeting mitochondria, was decorated on the surface of nanogels (Figure 4.7a).
Mitochondria localization of TPP-nanogel was then assessed in MDA-MB-231 cells using
CLSM. Colocalization of the red dots (from the Cy3-TPP-nanogel) and green dots (from
mitotracker green) as shown in figure 4.7c suggested the nanogels accumulated in the
mitochondria. In vitro cytotoxicity of PTX loaded TPP nanogel was then evaluated in
MDA-MB-231 cells. Control nanogels was indeed nontoxic, but when treated the cells with
PTX loaded nanogel, the cell viability decreased to 66%. Additionally, with TPP decoration
from 25% to 100% (molar ratio to PEG chain), the therapeutic effect of PTX could be
significantly enhanced, as suggested by the cell viability decrease from 57% to 31%
(Figure 4.7d).

Figure 4.7. Targeted delivery into mitochondria in MDA-MB-231 cells using triphenyl
phosphinium functionalized nanogel. a) Functionalization of nanogel with Cy3 and TPP,
b) cellular uptake of control nanogel (b) and folic acid functionalized nanogel (c) after 3 h
incubation (red, cy3-nanogel; green, mitotracker; orange, merged two channels). c) Cell
viability of empty nanogel and PTX loaded nanogel with varied TPP content from 0 to 100%
(eq. per PEG chain).
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4.2.5 Targeted drug delivery into nucleus
To further validate the applicability, we loaded our nanogel with another chemotherapy
drug DOX and then functionalized the nanogel with benzene boronic acid (BB) (Figure
4.8.a), aiming to target cell nucleus, where the drug could maximize its efficiency.35-38 For
this purpose, Cy3 labelled BB nanogel was firstly applied to MDA-MB-231 cells to
monitor their cellular uptake. After 3 hours incubation, we were excited to see significant
red fluorescence in the nucleus site of the cell, which perfectly colocalize with the nucleus
stain (Figure 4.8.c). Moreover, the BB functionalized DOX nanogel induced 81% cell death,
which is much more effective than DOX-nanogel without targeting ligands (Figure 4.8.d).

Figure 4.8. Targeted delivery into nucleus in MDA-MB-231 cells using benzene boronic
acid functionalized nanogel. a) Functionalization of nanogel with Cy3 and BB; Cellular
uptake of control nanogel (b) and BB functionalized nanogel (c) after 3 h incubation (red,
Cy3-nanogel; blue, hoechst; pink, merged two channels. d) Cell viability of empty nanogel
and DOX loaded nanogel with varied boronic acid content from 0 to 100% (eq. per PEG ).
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4.3 Summary
To summarize, we have developed a functional self-immolative nanogel system for the
encapsulation of chemotherapy drugs and the delivery of them into the cytosol and
subcellular organelles such as nucleus and mitochondria of cancer cells. This approach
perfectly meets all the requirements of an ideal drug delivery system by the following facts
(i) it takes very simple steps to prepare; (ii) therapeutic drugs are encapsulated with high
fidelity, i.e., high loading capacity and high stability (iii) the cargo is non-covalently
encapsulated without any modification; (iv) guest molecules can be released efficiently in
response to a target intracellular environment; (v) triggered polymer self-immolation
transforms the polymer from being amphiphilic to completely hydrophilic, which favors
the complete drug release; (vi) the nanogels can be easily and independently functionalized
with targeting ligands at the surface; and (vi) drug loaded nanogel can induce efficient cell
apoptosis. With all these exciting features installed in one nanogel system that is easy to
prepare, we believe it will serve as a potent drug delivery platform for a broad range of
small molecules and hold great potential for translational clinical research.
4.4 Experimental Procedures
4.4.1. General Methods
All the reagents were from commercial source and used as received. 1H NMR and

13

C

NMR spectra were recorded on a Bruker DPX-400 MHz NMR spectrometer using the
residual proton resonance of the solvent as the internal standard. All molecules without
characterization data mentioned below were synthesized through well-established
synthesis procedures previously reported by our group.39 Molecular weight of the polymers
was measured by gel permeation chromatography (GPC, Agilent) using a PMMA standard
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with a refractive index detector. THF was used as eluent with a flow rate of 1mL/min. UVvis absorption spectra were obtained by a Carry 100 Scan spectrometer. Fluorescence
spectra were recorded on a PerkinElmer LS 55 spectrofluorimeter. Dynamic Light
Scattering (DLS) data were recorded by a Malvern Nanozetasizer ZS90 with a 637-nm
laser source with non-invasive backscattering technology detected at 173o using disposable
sizing cuvette. For Transmission Electron Microscope (TEM) Study: The same sample for
DLS measurement was dropped onto carbon-coated copper grid. The grid was dried by
slow evaporation in air, and then dry separately in a vacuum overnight. Images were
recorded on a JEOL-2000FX electron microscopy operated at 200 kV and at a nominal
magnification of 5000X. At least 10 locations on the TEM grid were examined.
4.4.2. Polymer synthesis
Scheme 4.2 Synthesis route for polymer P1
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Synthesis of monomer 1: 2-hydroxylethylmathacrylate (1.3 g, 0.01 mol) was dissolved in
dry THF and then phosgene (15% wt in toluene) (1 eq. ) was added dropwise and kept at
room temperature for 3 hours, solvent was removed and then redissolved in
dichloromethane under ice bath, a mixture of triethylamine (2.02 g, 0.02 mol) and 2-
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hydroxylethyl-2-pyridyl disulfide (1.87 g, 0.01mol) in DCM was added dropwise, the
reaction mixture was then stirred at room temperature overnight. Solvent was removed and
redissolved in ethylacetate, the organic phase was then washed by NaHCO3 solution and
brine. The organic layer was then evaporated to dryness and purified by silica gel column
chromatography (0-30% ethyl acetate in hexanes) to afford 2.3 g (67% yield) of 1. 1H NMR
(400 MHz, CDCl3) δ 8.47-8.49 (d, J = 8 Hz, 7.6 Hz, 2H), δ 7.61-7.68 (m, 2H), δ 7.08-7.12
(m, 1H), δ 6.14 (s, 1H), δ 5.60 (s, 1H), δ 4.37-4.43 (m, 4H), δ 3.06-3.10 (t, J = 6.6 Hz, 2H),
δ 1.94 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 167.2, 159.6, 154.8, 149.9, 137.1, 135.9,
126.4, 121.1, 120.1, 65.9, 65.7, 62.4, 37.1, 18.4. ESI-MS (expected: [m+H]+= 344.0548,
obtained: [m+Na]+= 366.0685)
Synthesis of chain transfer reagent (PEG5000-cta) : To a solution of O-(2-Aminoethyl)O′-[2-(Boc-amino)ethyl]decaethylene glycol (0.5 g, 0.1 mmol) and triethylamine (0.0612
g, 0.6 mmol) in DCM was added 4-Cyano-4-(phenylcarbonothioylthio)pentanoic acid Nsuccinimidyl ester (0.18 g, 0.5 mmol) solution, the mixture was kept stirring overnight at
room temperature. Solvent was removed then dialyzed against DCM/MeOH to get purified
PEG-CTA. (0.51 g, 94% yield). 1H NMR (400 MHz, CDCl3) δ 7.89-7.91 (d, J = 8.0 Hz
1H), δ 7.54-7.57 (t, J = 7.2 Hz, 7.6 Hz, 1H), δ 7.37-7.41 (t, J = 8 Hz, 7.6 Hz, 2H), δ 6.37
(s, 1H), δ 5.03 (s, 1H), δ 3.30-3.81 (m, 454H), δ 2.41-2.69 (m, 4H), δ 1.93 (s, 3H), δ 1.43
(s, 9H). 13C NMR (100 MHz, CDCl3) δ 170.4, 144.6, 132.9, 128.6, 126.7, 118.7, 70.6,
70.2, 69.7, 50.8, 46.1, 40.6, 39.5, 34.2, 31.6, 28.4, 24.1. GPC (THF): 6.4 kDa, Đ= 1.02.
Synthesis of polymer P0: A solution of 1 (103 mg, 0.3 mmol), PEG-CTA (150 mg, 0.03
mmol) and AIBN (0.984 mg, 0.006 mmol), in THF (400 uL) was degassed by three freeze-
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pump-thaw cycles before being sealed off under argon protection and vaccum. After 6 h at
65 °C, the polymerization media was diluted in dichloromethane and condensed using
rotavap, precipitated in diethyl ether for 3 times to remove unreacted monomers. The
precipitate was collected and dried under vacuum to yield 233 mg (92% yield) of P0. GPC
(THF): Mn= 9.2 K Da, Đ= 1.02. 1H NMR (400MHz, CDCl3) δ 8.45, 7.66, 7.09, 4.17-4.39,
3.45-3.81, 3.08, 1.55-1.96, 1.43, 0.85-1.20. 13C NMR (100 MHz, CDCl3) δ 159.4, 154.6,
149.8, 137.2, 121.0, 119.9, 70.5, 70.2, 65.6, 62.4, 53.4, 36.9, 29.7, 28.4. From 1H NMR,
integration of f and d provided the molar ratio of PEG/PDS.

Figure 4.9. NMR spectrum of polymer P0 and P1
Synthesis of polymer P1: P0 was dissolved in DCM/TFA (1mL/1mL) mixture and stirred
overnight at room temperature. The solvent was evaporated and redissolved in DCM, the
solution was then dialyzed against DCM/MeOH to get purified P1 (95% yield). GPC (THF):
Mn= 9.2 K Da, Đ= 1.05. 1H NMR (400MHz, CDCl3) δ 8.50, 7.76, 7.18, 4.18-4.39, 3.453.87, 3.09, 1.75-1.96, 0.85,1.02. 13C NMR (100 MHz, CDCl3) δ 160.0, 159.3, 155.2,150.4,
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138.5, 138.1, 122.2, 121.8, 120.8, 71.0, 70.6, 66.3, 63.2, 40.8, 37.6, 30.4. Disapperance of
peak i at 1.43 ppm confirmed the successful deprotection.
4.4.3 Competition between crosslinking and self-immolation
Scheme 4.3 Mechanism of crosslinking and self-immolation induced by DTT
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4.4.4. Nanogel preparation
(a) Control nanogel: Deionized water was added to the polymer (5 mg/mL) solution in THF
(100 uL) and stirred overnight to allow THF to evaporate. Nanogels were achieved by
chemically cross-linking this equilibrium assembly of the polymer at 25 °C using a
calculated amount of DTT for 4 h as reducing agent as previously reported.40,41 Crosslinking was determined by calculating the amount of byproduct 2-pyridinethione using its
molar extinction coefficient (8.08 × 103 M–1 cm–1 at 343 nm) by UV–vis spectroscopy. The
size and zeta potential of these nanogel samples were then measured by dynamic light
scattering at 0.2 mg/ml.
(b) Guest encapsulation: Polymer solutions in deionized water were stirred at room
temperature and DiI/PTX/DOX stock solution (15 mg/mL in acetone) was added according
to designated feeding ratio from 10% to 30%. The solutions were stirred for 8 h in room
temperature and calculated amount of DTT was then added to crosslink the micelles to
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generate guest encapsualted nanogel. The solution was then purified by dialysis against
water for 3 days.
Standard curve of DOX was determined using absoprtion at 510 nm of a set DOX samples
at varied concentration (Figure 4.10.a). The amount of encapsulated DOX in nanogel was
then calculated from the standard curve. To determine the amount of encapsulated PTX,
1mg/ml nanogel-PTX solution was first treated with GSH to release the drug, the mixture
was lyophilized and then redissolved in THF for GPC measurement using the UV detector
at 220 nm. The loaded PTX amount can be then calculated from the standard curve, which
was obtained by measuring PTX peak area at different concentrations using GPC (THF).
(Figure 4.10.b).
To achieve the maximum drug loading capacity, we have optimized the crosslinking
density, drug feeding ratio and polymer hydrophobicity. Nanogel with 20% crosslinking,
30% drug feeding ratio and PEG:PDS ratio at 1:10 showed the highest drug loading
capacity, this condition was used for the following cell culture experiments. The
encapsulation efficiency (EE) and loading capacity (LC) were calculated based on the
following formulas:
EE, % = Absorption of loaded drug/absorption of initial feeded drug ×100%
LC, % = Amount of “encapsulated” drug / amount of polymer ×100%
(c) Ligands modification: Nanogel formed by P1 can be functionalized with Cy3/folic
acid/triphenylphosphinium/benzene boronic acid by reacting with corresponding NHS
ester in PBS buffer pH 8.5, functionalized nanogel was then purified through dialysis
against deionized water. To vary the ligand density, mix polymer P0 and P1 with calculated
amount and prepare nanogel following the same protocol as described in a) and b).
80

Figure 4.10. Standard curve of a) DOX based on absorption, b) PTX based on GPC peak
area.

Figure 4.11. Characterization of ligand decorated nanogels: a) absorption at 345 nm
suggested folic acid attachment, b) Boronic acid modification shifted the nanogel charge
from positive to negative; absorption increase at 290 nm (c) and nanogel size increase (d)
confirmed the Ph3P modification.
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4.4.5. Cell Culture
A human breast cancer cell line MDA-MB-231and human liver carcinoma cells Hep G2
and healthy T293 kidney cell line were grown in DMEM supplemented with 10% (FBS),
1% l-glutamine, and 1% antibiotic-antimycotic (comprised of 100 units/mL penicillin and
100 μg/mL of streptomycin). All cells were grown at 5% CO2 and 37 °C. Digestion of cells
for culture was performed according to protocols from ATCC.
(a) Cell viability assay: Cells were seeded on flat-bottom 96-well tissue culture plates at a
density of 5000 cells/well and rested for 24 h at 37 °C in 5% CO2. After overnight
incubation, the culture medium was removed, and cells were treated with empty or drug
loaded nanogel samples at different concentrations in complete medium for 48 h. After
treatments, cells were washed and medium was replaced with 3-(4,5-dimethylthiazol-2-yl)
2,5-diphenyltetrazolium solution (MTT) (prepared as 0.5 mg/mL in medium) and further
incubated for 3–4 h at 37 °C. Remove 75 ul of medium and add 50 uL DMSO to each well
and incubate for another 10 mins. Purple color formation was observed and recorded using
a plate reader at 540 nm.
(b) Confocal imaging: Cells were seeded at 30–50% confluency (∼10,400 cells/cm2) in 4chamber 35 mm glass bottom dishes and incubated overnight at 37 °C in 5% CO2 before
performing uptake. Culture media was removed, and cells were washed with PBS one time
before adding new culture media containing Cy3-labeled nanogels diluted to 0.1 mg/mL in
DMEM (10× , diluted to 1× with PBS). Samples were incubated for 2 h. Nuclear staining
(NucBlue, 80 μL/mL of media) and mitotracker green was added in the final 30 min of
incubation. Medium was removed from cells, which were washed with PBS three times;
then, live cell imaging buffer was added for confocal imaging. Assessment of Cy3-
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conjugated nanogel intracellular uptake was recorded using 560 nm laser, and nuclear stain
was detecting using a 405 nm wavelength laser, mitotracker green was detected using a
488 nm wavelength laser. Confocal microscopy was performed on a Nikon Yokogawa
spinning disk confocal microscope equipped with 40× oil or 60× oil objectives and an
Andor EMCCD camera. Co-localization of blue (hoechst) and red (cy5) channels was
studied to check the nuclei of cells.
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CHAPTER 5
CELL REGULATED NANOGEL ACCUMULATION IN TARGET CELLS
5.1 Introduction
Off-target accumulation of nanoparticles, especially for in vivo tumor imaging and
therapeutics, is one of the major hurdles preventing nanoparticles from being successfully
translated and commercialized for biomedical application. Thus, tremendous efforts have
been taken to develop the capability of on-target accumulation. These attempts mainly
focus on optimizing the so-called enhanced permeation and retention (EPR) effect and on
introducing ligand-receptor interactions for active targeting. Though certain nanoscopic
objects seem to have the capability of enhancing accumulation in tumor tissues due to EPR
effect, attributed to defective tumor vasculature and impaired lymphatic drainage, their
effectiveness in nanomedicine is significantly impeded by the inherent heterogeneity of
tumors.1-6 Alternatively, active targeting where complementary ligands are incorporated
onto nanocarriers to recognize receptors overexpressed in tumor cells has been explored
for selective tumor localization.7-10 However, presence of low level of receptors in offtarget locations can still accumulate ligand-decorated nanocarriers, which gives poor
selectivity gain and hampers the efficacy of active targeting in vivo.
To enhance the selectivity of active targeting, ligand masking strategies in which
ligands are masked and availabilities are only revealed in response to disease
microenvironment until they reach targets have been developed. But current strategies
developed for ligand unmasking are primarily focused on using secondary imbalances in
disease including escalated acidity, redox potential and external stimuli such as ultraviolet
light that does not have the penetration depth to be useful.11-17 A more effective approach
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involves the primary imbalance in the disease microenvironments - enzymes to trigger
ligand exposure.18-23 Past approaches in this regard involves noncovalent, steric protection
of ligand with enzyme-cleavable bulky groups (e.g. PEG) that decrease the accessibility of
ligand to bind with receptors. These approaches require extensive engineering but also
have limited targeting capability due to the slow cleavage kinetics.
Here, we propose a cellular AND gate to utilize cell itself to regulate cell-nanoparticle
interactions and achieve highly selective targeting (Figure 5.1). Alkali phosphatase (ALP)
and carbonic anhydrase IX (CA IX) are two disease-relevant enzymes overexpressed on
cell surface.24-27 Nanogels are firstly designed in such a way that they will only accumulate
in specific disease cells which overexpress both these two types of enzyme, which is termed
as ‘single cellular AND gate’. If each enzyme is presented on different cell type, the uptake
of nanoparticles into the CA IX overexpressed cells could be greatly promoted by cells
overexpress ALP which could reveal the cell interactive functionalities on the nanoparticles,
this is termed as ‘intercellular AND gate’ (Figure 5.2). Since enzymes are considered to be
the primary cause of pathological imbalances in biology, these dual enzymes based cellular
AND gated nanoparticle uptake would open up more possibilities for tumor imaging,
diagnosis and targeted delivery.

Figure 5.1 Schematic representation of single cellular AND gated nanogel uptake
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Figure 5.2 Schematic representation of intercellular AND gated nanogel uptake
5.2 Results and discussion
5.2.1 Design and synthesis
Our molecular design involves covalently mask binding motif for CA IX on nanogel
with alkaline phosphatase (ALP) substrates through a self-immolative linkage to suppress
nanoparticle cell interaction and cellular accumulation. Since cell membrane interactive
functionalities are covalently masked, their availability for cell interaction will be
completely eliminated. We hypothesize that ALP overexpressed cells will cleave the
readily accessible substrate on nanogel surface to rapidly liberate the sulphonamide ligands
for interaction with CA IX overexpressed cells. Thus, concurrent presence of ALP and CA
IX on one cell type would generate a cellular AND gate to achieve specific and rapid
cellular accumulation.
The molecular design strategy is shown in Fig. 5.3. The nanogels will be synthesized
from a block copolymer that is composed of three components, crosslinkable hydrophobic
coumarin methacrylate block, a polyethylene glycol block providing hydrophilicity to
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drive the self-assembly of nanogel, and a phenylsulphonamide, masked with a selfimmolative phosphate substrate, was attached to chain end of the block polymer backbone.

Figure 5.3 Chemical structures of polymeric nanogel and ALP induced exposure of
sulfonamide ligands
5.2.2 Nanogel preparation and characterization
Due to the amphiphilic nature of polymer P2, we attempted to prepare nanoassemblies
by distributing P2 in water. The nanoassembly formed was found to have an apparent
hydrodynamic diameter of >120 nm (Figure 5.4) using dynamic light scattering (DLS).
The hydrophobic core of the nanoassembly was constituted of coumarin moieties, which
are known to dimerize under UV irradiation (>350 nm).28-29 When expose the
nanoassemblies to UV light, dimerization of coumarin would crosslink the hydrophobic
interior and stabilize the nanoassemblies to generate nanogels. Decrease of UV absorption
of coumarin moieties supported this crosslinking process (Figure 5.4c). Crosslinking
density can be easily tuned by varying the time of UV exposure. We also noticed that the
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crosslinked nanogel have a similar size to the nanoassemblies before crosslinking (Figure
5.4 b).
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Figure 5.4 a) Preparation of nanogel; b) DLS profile of micelle and crosslinked nanogel;
c) UV induced crosslinking of micelles.
5.2.3 Competitive binding assay
Our design hypothesis is that the polymeric nanogel will not be capable of binding to
target enzyme carbonic anhydrase until the presence of ALP covalently cleave the
phosphotase mask to reveal the sulfonamide ligands. To test this hypothesis, we tested
whether proposed nanogel as the ligands can bind to bCA using a competitive displacement
assay where 5-(Dimethylamino)-1-naphthalenesulfonamide (DNSA) is used as the initial
ligand, the fluorescence emission at 460 nm formed by DNSA-bCA complex indicates
whether DNSA is replaced (Figure 5.5a). Our studies showed that when the ligands on the
nanogel were masked by the phosphate moiety, it did not competitively remove DNSA,
suggested by the little change of fluorescence intensity before and after nanogel was added.
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However, when added ALP to this system, significant fluorescent signal decrease was
observed over 30 minutes, indicating the unmasked nanogel was able to displace DNSA
(Figure 5.5b).

Figure 5.5 a) Schematic representation of competitive binding assay; b) Emission spectrum
of DNSA-bCA complex after treating with nanogel and ALP.
5.2.4 Intracelluar uptake of nanogels gated by ALP and CA9 in SAOS-2 cells
Following this exciting finding, we then want to further test this nanogel system in vitro.
SAOS-2 is a human osteosarcoma cell line which overexpresses both ALP and CA9. We
designed a set of experiments listed in table 5.1, by treating the SAOS-2 cells with ALP
inhibitor or CA9 inhibitor or the combination of these two, we are able to design
experiments to test whether the cellular uptake of the designed nanogels follows the AND
gate.
92

Table 5.1. Experimental variations to create AND gated conditons
SAOS-2 cell line

Treated with ALP
inhibitor

Treated with CA9
inhibitor

a

✅

❎

b

❎

✅

c

✅

✅

d

❎

❎

Figure 5.6 a) Flow cytometry histograms of SAOS-2 cells (with/without inhibitor treatment)
after 2 hours incubation with DiI loaded nanogels, b) statistic data showing the DiI loaded
nanogel accumulation in SAOS-2 cells.
We hypothesized that SAOS-2 cells treated with either one of the enzyme inhibitors or the
combination of these two would not uptake the nanogels efficiently, only the control cells
without any inhibitor treatments would be observed significant nanogel accumulation. To
test this hypothesis, we loaded the nanogel with a hydrophobic dye, 1,1'-dioctadecyl3,3,3'3'-tetramethyl-indocarbocyanine perchlorate (DiI), to track and quantify the cellular
uptake using flow cytometry and confocal laser scanning microscopy. We were excited to
find that nanogel accumulation in non-treated cells is significantly higher than cells treated
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with either ALP or CA IX inhibitors (Figure 5.6). These findings supported our hypothesis
that ALP and CA IX need to be concurrently present for the nanogels to be uptaken
efficiently.
We are then excited to evaluate the selectivity of nanogels over four different cell lines.
If proposed AND gate mechanism is operating in this case, the accumulation of nanogels
will be only observed in the human osteosarcoma Saos-2 cells, where ALP and CA9 are
concurrently overexpressed. The absence of either protein expression in the other cell lines
will suppress the accumulation of nanogels. This possibility was tested using Saos-2
(ALP+, CA9+), MDA-MB-231(ALP+, CA9-), HT-1080 (ALP-, CA9+) and MCF-7 (ALP-,
CA9-) cell lines. Indeed, DiI loaded nanogels are readily taken up by SAOS-2 (ALP+, CA+)
cells, but not by MDA-MB-231 (ALP+), MCF-7 (ALP-, CA-), or HT-1080 (CA+) cells,
as shown in Figure 5.7.

Figure 5.7 a) Flow cytometry histograms of SAOS-2 cells, MCF-7, HT1080, MDA-MB231 cells after 2 hours incubation with DiI loaded nanogels, b) statistic data showing the
DiI loaded nanogel accumulation in four cell lines.

94

5.2.5 Enhanced nanogel cellular uptake regulated by a second cell line
Membrane vesicle trafficking plays an important role in intercellular communication so
that multitypes of cells could work together to maintain the biofunctions. Inspired by this,
we have tried to coculture HT-1080 (CA+) and MDA-MB-231 (ALP+) cells and then
incubated with DiI loaded nanogels. Although these assemblies do not readily enter HT1080 (CA+) cells or MDA-MB-231 (ALP+) cells when they were cultured separately, we
have observed a significant nanogel accumulation in HT-1080 (CA+) cells when they are
cocultured with MDA-MB-231 (ALP+), where the cell surface ALP in the latter cell line
processes the nanogels to be taken up by the former cells after binding to the carbonic
anhydrase. These results were displayed in Figure 5.8.
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Figure 5.8 Flow cytometry dual fluorescence density plot histograms of HT1080 and
MDA-MB-231 coculture (nanogel was loaded with DiI dye, one of the cell lines was
stained with membrite dye), a) MDA-MB-231 and stained HT1080, b) Histogram of
nanogel uptake in these two cell lines, c) MDA-MB-231 and stained HT1080 coculture, d)
Histogram of nanogel uptake in two cell lines.
5.3 Summary
In summary, we have demonstrated a set of cellular logic gates that exhibit efficient
nanogel uptake in target cells in the presence of two different proteins. Stable nanogels
with dye loading property have been designed and utilized to evaluate the cellular logic
gates. We outline molecular designs that can be uptaken selectively by SAOS-2 cells
overexpress both ALP and CA IX, as well as enhanced uptake in HT1080 cells promoted
by cocultured MDA-MB-231 cells. The nanogel system was developed by caging a
carbonic anhydrase-specific ligand with an ALP cleavable phosphate group that masks the
ligand from being available for protein binding and following cellular accumulation. For
the programmed single cellular AND gate, it requires the concurrent presence of both ALP
and CA IX for selective accumulatin only in SAOS-2 cells. Enhanced nanogel uptake into
HT1080 cells was further promoted by cocultured MDA-MB-231 cells following the
intercellular AND gate where MDA-MB-231 cells firstly process the nanogels by
romoving the phosphate mask and reveal the ligands so that they can bind with CA IX in
HT1080 cells and get uptaken. The design insights and the concept of cellular AND gates
provided here will find use in the design of novel protein-responsive drug delivery and
highly selective tumor imaging.
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5.4 Experimental
5.4.1 General Methods
All the reagents were from commercial source and used as received. 1H NMR and

13

C

NMR spectra were recorded on a Bruker DPX-400 MHz NMR spectrometer using the
residual proton resonance of the solvent as the internal standard. Molecular weight of the
polymers was measured by gel permeation chromatography (GPC, Agilent) using a PMMA
standard with a refractive index detector. THF was used as eluent with a flow rate of
1mL/min. UV-vis absorption spectra were obtained by a Carry 100 Scan spectrometer.
Fluorescence spectra were recorded on a PerkinElmer LS 55 spectrofluorimeter. Dynamic
Light Scattering (DLS) data were recorded by a Malvern Nanozetasizer ZS90 with a 637nm laser source with non-invasive backscattering technology detected at 173o using
disposable sizing cuvette. For Transmission Electron Microscope (TEM) Study: The same
sample for DLS measurement was dropped onto carbon-coated copper grid. The grid was
dried by slow evaporation in air, and then dry separately in a vacuum overnight. Images
were recorded on a JEOL-2000FX electron microscopy operated at 200 kV and at a
nominal magnification of 5000X. At least 10 locations on the TEM grid were examined.
5.4.2 Polymer synthesis
Synthesis of L0: small molecule a and b were synthesized according to previously reported
procedures. Molecule a (298 mg, 1 mmol) was dissolved in dry THF at 0 oC and then
molecule b (536 mg, 1.2 mmol) and triethylamine ( 203 mg, 2 mmol) was added dropwise
and kept at room temperature for 8 hours, solvent was removed and then redissolved in 20
mL dichloromethane, the organic phase was then washed by brine (3*30 mL). The organic
layer was then evaporated to dryness and purified by silica gel column chromatography (097

30% ethyl acetate in hexanes) to afford 318 mg (45 % yield) of L0. 1H NMR (400 MHz,
CDCl3) δ 8.21-8.19 (d, J = 8.8 Hz, 2H), δ 8.12-8.10 (d, J = 8.4 Hz, 2H), δ 7.32 (m, 10H),
δ 7.17-7.15 (d, J = 8.4 Hz, 2H), δ 5.12-5.10 (d, J = 8.4 Hz, 4H), δ 5.02 (s, 2H), δ 2.9 (s,
4H). ESI-MS (expected: [m+H]+= 709.1179, obtained: [m+Na]+= 731.6345)
Scheme 5.1 synthesis route for phosphate ligand and target polymer
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Synthesis of L1: Molecule L0

O

(300 mg, 1 mmol) was dissolved in anhydrous

dicholoromethane at 0 oC under argon protection and then TMSBr (130 mg, 2 mmol) was
added dropwise and kept at room temperature for 1 hour, 2 drops of water was added to
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the reaction mixture and let it stir for another two hours, white precipate was collected
through filtration and washed three times with cold DCM. The prodcut was collected as
white powder and generated 201 mg (90 % yield) of L0. 1H NMR (400 MHz, CDCl3) δ
8.33-8.31 (d, J = 8 Hz, 2H), δ 8.18-8.16 (d, J = 8.4 Hz, 2H), δ 7.32-7.30 (d, J = 8.4 Hz,
2H), δ 7.21-7.19 (d, J = 8.4 Hz, 2H), δ 5.07 (s, 2H), δ 2.94 (s, 4H). ESI-MS (expected:
[m+H]+= 529.0240, obtained: [m+Na]+= 551.3352)
Synthesis of P0: A solution of M (103 mg, 0.3 mmol), PEG-CTA (150 mg, 0.03 mmol)
and AIBN (0.984 mg, 0.006 mmol), in THF (400 uL) was degassed by three freeze-pumpthaw cycles before being sealed off under argon protection and vaccum. After 6 h at 65 °C,
the polymerization media was diluted in dichloromethane and condensed using rotavap,
precipitated in diethyl ether for 3 times to remove unreacted monomers. The precipitate
was collected and dried under vacuum to yield 233 mg (93% yield) of P0. GPC (THF):
Mn= 8.8 K Da, Đ= 1.02. 1H NMR (400 MHz, CDCl3) δ 7.45, 6.80, 6.79, 6.07, 3.97, 3.83,
3.66, 3.48, 2.36, 1.96, 1.82, 1.67, 1.50, 1.46, 1.26, 1.06, 0.89. From 1H NMR, integration
of peak at δ 6.07 and δ 3.83 provided the molar ratio of PEG/PDS to be 1:10.

Synthesis of polymer P1: P0 was dissolved in DCM/TFA (1mL/1mL) mixture and stirred
overnight at room temperature. The solvent was evaporated and redissolved in DCM, the
99

solution was then dialyzed against DCM/MeOH to get purified P1 (95% yield). GPC
(THF): Mn= 8.2 K Da, Đ= 1.05. 1H NMR (400MHz, CDCl3) δ 7.43, 6.78, 6.67, 6.05, 3.95,
3.81, 3.63, 3.45, 2.34, 1.97, 1.80, 1.66, 1.43, 1.24, 1.04, 0.87. Disapperance of peak i at
1.50 ppm confirmed the successful deprotection.

Synthesis of polymer P2: P1 (100 mg), triethylamine (5 uL) and ligand L1 (8.8 mg, 10 eq.)
was dissolved in DCM and stirred overnight at room temperature. The solvent was
evaporated and redissolved in DCM, the solution was then dialyzed against DCM/MeOH
to get purified P2 (95% yield). GPC (THF): Mn= 9 K Da, Đ= 1.05. 1H NMR (400MHz,
CDCl3) δ 8.22-8.15, 7.45-7.41, 6.78, 6.67, 6.05, 5.13, 3.95, 3.81-3.45, 2.92, 2.33, 1.80,
1.65, 1.45, 1.27, 1.05, 0.87. New peaks at δ 8.22-8.15, δ 7.45-7.41 and δ 5.13 ppm
confirmed the ligand modification.
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5.4.3 Nanogel preparation and characterization
DiI loaded nanogel: Polymer solutions (5 mg/mL) in deionized water were stirred at room
temperature and DiI stock solution (5 mg/mL in acetone) was added according to
designated feeding ratio 5 wt%. The solutions were stirred for 8 h in room temperature and
filtered with 0.45 um PTFE filter to remove unencapsulated dye molecules. Cross-linking
was done by exposing polymer solutions to UV irradiation (365 nm) for 2 minutes. The
size of these nanogel samples were then measured by dynamic light scattering at 0.2 mg/ml.
5.4.4 Cellular uptake
Human breast cancer cell lines MDA-MB-231 and MCF-7, a fibrosarcoma cell line
HT1080, a human osteosarcoma cell line SAOS-2 were grown in DMEM supplemented
with 10% (FBS), 1% l-glutamine, and 1% antibiotic-antimycotic (comprised of 100
units/mL penicillin and 100 μg/mL of streptomycin). All cells were grown at 5% CO2 and
37 °C. Digestion of cells for culture was performed according to protocols from ATCC.
a) Confocal imaging: Cells were seeded at 30–50% confluency in 8-well ibidi chamber
glass bottom dishes and incubated 12 hours at 37 °C in 5% CO2 before performing
uptake. Culture media was removed, cells were washed with PBS one time before
adding new culture media containing DiI loaded nanogels diluted to 0.0375 mg/mL in
DMEM. Samples were incubated for 1 h. Nuclear staining (NucBlue, 80 μL/mL of
media) was added in the final 30 min of incubation. Medium was removed from cells,
which were washed with PBS three times; then, live cell imaging buffer was added for
confocal imaging. Assessment of nanogel intracellular uptake was recorded using 560
nm laser, and nuclear stain was detecting using a 405 nm wavelength laser. Confocal
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microscopy was performed on a Nikon Yokogawa spinning disk confocal microscope
equipped with 40× oil or 60× oil objectives and an Andor EMCCD camera.
b) Flow cytometry: For single cellular uptake experiments, each cell type was seeded at
the following density in a 12-well glass bottom dish and maintained at 37 °C overnight
in 5% CO2 for 12 hours before performing uptake: MDA-MB-231 at 15K cells/mL,
HT1080 at 10K cells/mL, MCF-7 at 15K cells/mL, SAOS-2 at 30K cells/mL. Culture
medium was removed, and cells were washed with PBS one time before adding new
culture medium containing DiI loaded nanogels diluted to 0.0375 mg/mL in DMEM
(10Å~ , diluted to 1Å~ with PBS). Samples were incubated for 1h, then washed with
PBS, trypsinized, and collected by centrifugation. The cells were resuspended in 200
μL of PBS buffer and stored at 4°C. A minimum of 100,000 cells were analyzed for
each sample using a BD LSRFortessa.
For cocultured cellular uptake experiments, coculture of stained MDA-MB-231 and
unstained HT1080 cells at a seeding ratio of 3:2 were seeded in 6-well glass bottom
dish for 12 hours and then following same procedures as above. Similar procedures
also applied to the coculture of unstained MDA-MB-231 and stained HT1080 cells.
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CHAPTER 6
SUPRAMOLECULAR ASSEMBLIES FOR PROTEIN TRANSPORT ACROSS
SOLVENT INTERFACE
Adapted with permission from Gao, J.; Zhao, B.; Wang, M.; Serrano, M. A. C.; Zhuang,
J.; Ray, M.; Rotello, V.; Vachet, R. W.; Thayumanavan, S. “Supramolecular Assemblies
for Transporting Proteins Across an Immiscible Solvent Interface” J. Am. Chem. Soc., 2018,
140, 2421–2425. Copyright © 2018 American Chemical Society
6.1 Introduction
Transporting molecules across incompatible interfaces is a significant challenge,
especially for macromolecules. A striking example of an interfacial barrier is the cellular
membrane, where an organized presentation of hydrophilic and hydrophobic functional
groups provides a formidable barrier for molecular transport.1 While small hydrophobic
molecules can passively transport across this membrane barrier and small ionic molecules
can be transported through natural or artificial ion channels, globular proteins with large
hydrophilic surfaces offer no easy access. 2,3 Nonetheless, cells do transport proteins when
necessary

for

inter-cellular

communication,

often

using

nanoscopic

vesicular

compartments called exosomes.4,5 Inspired by these cell-derived vesicles, we became
interested in exploring the possibility of transporting proteins into a nanoscopic
compartment across a solvent interface. While simply transporting proteins across
interfaces has many implications, selective transport, while retaining structure and function,
could be transformative in applications such as sensing, delivery, and diagnostics.
Supramolecular assemblies have already shown great potential in these areas6-8 and
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supramolecular protein transport would add to this armor. Reverse micelle systems from
small molecule surfactants have shown the potential to solubilize proteins in organic
solvent, however, the stability can be easily affected by a lot of factors such as salt and
pH.9-11 Also, the selectivity of these systems is quite limited. Herein, we report a simple
supramolecular approach based polymeric platform that selectively transports watersoluble globular proteins from an aqueous phase to the water-pool of a reverse micelle in
an apolar organic phase (Figure 6.1).
We outline two strategies to selectively shuttle protein molecules from an aqueous phase.
In the first approach, we rely on complementary electrostatic interactions to bind proteins
in an aqueous phase and ferry them over to the interior of a reverse micelle in an apolar
solvent such as toluene. In a second approach, we explore the use of specific ligand-protein
interactions to selectively transport proteins from an aqueous phase into an apolar phase.

Figure 6.1. Schematic representation of reverse micelle driven protein transportation.
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6.2 Results and discussion
6.2.1 Molecular design and synthesis
For the initial proof-of-concept, we first synthesized a polystyrene-based amphiphilic
random copolymer P1 (Mn= 11 kDa, Đ=1.09) (Figure 6.2a). This anionic polymer,
achieved using nitroxide-mediated polymerization, comprises of 40% p-decyloxystyrene
as the hydrophobic monomer and 60% of p-oxyacetyl-styrene as the hydrophilic monomer.
A corresponding cationic polymer, P2, was obtained by coupling the carboxylate acid
moiety in P1 with N,N-dimethylethylenediamine under EDC-coupling conditions,
followed by quaternization of the tertiary amine with methyl trifluoromethanesulfonate
(Figure 6.2b).
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Figure 6.2. Structural features of polymeric reverse micelles. Molecular structure of
polymer P1 (Mn= 11 kDa, Đ= 1.09) a) and P2 b) (Mn= 12 kDa, Đ= 1.15), c) DLS profile
of P1 and P2 in toluene, TEM of P1(d) and P2(e).
6.2.2 Reverse micelle preparation and characterization
The possibility of these polymers forming a reverse micelle assembly was tested by
distributing these polymers in toluene along with two equivalents of water per carboxylate
or quaternary ammonium moiety. The water molecules are added to provide a ‘water pool’
for the reverse micelles. Assemblies with a fairly homogeneous size distribution of 50 nm
for P1 and 37 nm for P2 were observed, as discerned by both dynamic light scattering
(DLS) (Figure 6.2c) and transmission electron microscopy (TEM) (Figure 6.2d-e).
6.2.3 Electrostatic interaction driven protein transport
The key premise for the work here is that the polymers would self-assemble in apolar
solvents, bind to complementarily charged proteins in the aqueous phase, and ferry them
across the interface to the interior of the reverse micelles in toluene. To test this possibility,
porcine liver esterase (plE, MW = 168 kDa) was used as the model protein, because this
protein is negatively charged enzyme at pH 8.0 (isoelectric point pI = 5.3). We used reverse
micelles based on the cationic polymer P2. Upon equilibrating an aqueous solution
containing plE with a toluene solution containing P2 (1 mg/mL) reverse micelles, the
presence of proteins in both phases was detected using matrix assisted laser
desorption/ionization mass spectrometry (MALDI-MS). Figures 6.3a and 6.3b show the
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Figure 6.3. MALDI-MS analysis of a) aqueous phase before equilibration, b) organic
phase before equilibration, and c) the organic phase after equilibration. d) Activity of
esterase (based on substrate cleavage) inside reverse micelles compared with esterase
activity in bulk aqueous phase.
mass spectrum of the aqueous and organic phases, respectively, before equilibration. After
equilibration, we were gratified to observe the presence of a peak corresponding to plE in
the organic phase (Figure 6.3c), suggesting that plE was successfully transported into
interior of the reverse micelles.
In order to quantify the extent of protein that was encapsulated within the reverse micelles,
we analyzed the organic phase for proteins using the bicinchoninic acid (BCA) assay. This
analysis showed that 1 mg of polymer is capable of transporting and binding to 0.05 mg of
plE, an equivalent of 5 wt% loading capacity. This capacity compares much more favorably
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Figure 6.4. a) SDS-PAGE for transport and release of plE from reverse micelles; b)
Intensity value for each band of SDS-PAGE; c) Standard curve of plE based on SDS-PAGE.
than the typical loading capacity of proteins in liposomes.15 When treated the organic phase
with THF and acidic solution, we found that the plE can be released into the aqueous phase,
as shown in the SDS-PAGE analysis of organic phase and aqueous phase before and after
equilibration (Figure 6.4).
A more compelling analysis is to identify whether the enzyme molecules, which were
extracted into the organic phase, remain active. To investigate this possibility, we
synthesized a substrate for plE that is amenable for use both in organic and aqueous phases
(Scheme 6.1). If we were to use water-soluble substrates and investigate the activity in the
reverse micelles using an apolar solvent, we would likely get a solvophobically driven
concentration increase of the substrate, which could be interpreted as an increase in
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enzymatic activity in the reverse micelle. Instead, we were interested in truly estimating
the activity of the enzyme. Therefore, we designed and synthesized an amphiphilic
coumarin-based profluorophore S1. The alkylated phenolic state of this substrate causes
this molecule to be non-fluorescent. When the ester bond of S1 is cleaved by the enzyme,
the resultant hemiacetal rapidly degrades to generate umbelliferone, a fluorescent coumarin
molecule.
Scheme 6.1. Substrate cleavage in present of esterase
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The substrate itself was quite stable in PBS buffer as well as after equilibration with
toluene solution containing P2. In the presence of plE, however, a rapid hydrolysis of S1
to generate the fluorescent umbelliferone was observed (Figure 6.3d). We then analyzed
the possibility of this reaction in toluene in the presence of reverse micelles loaded with
plE. Interestingly, the hydrolysis rate was found to be quite similar to that of the free
enzyme. As the estimated concentration of the enzyme inside the reverse micelle and the
free plE in the aqueous phase in the two experiments above are the same, these results were
taken to suggest that the activity of plE is maintained inside the reverse micelles. As another
control experiment, we were interested in finding whether the electrostatic complex
between P2 and plE has any inherent effects upon the activity of the latter. To test this, we
mixed plE and P2 in aqueous phase and found that the activity of the enzyme was slightly
lower, suggesting that interactions between P2 and plE have little effect on plE activity.
When considering the pathway by which these polymers could transport proteins across
the interface, two limiting possibilities can be proposed. Note that these polymers can form
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micelle-like assemblies in the aqueous phase and reverse-micelle-like assemblies in the
apolar toluene phase. Therefore, it is possible that the polymers equilibrate themselves
between the two phases. The resultant thermodynamic equilibrium between the two solvent
phases, combined with the complementary binding affinity to the proteins, cause proteins
to be extracted to the organic phase. Alternately, the exchange of water molecules between
the interior of the reverse micelle and the bulk water (in the biphasic mixture) ferry proteins
into the interior of the reverse micelles. If there is an affinity between the protein and the
functional groups within the interior of the assembly, then the proteins would stay in the
reverse micelle. In this latter scenario, the polymer assemblies remain kinetically trapped
as reverse micelles in the organic phase. To differentiate these two pathways, we
equilibrated the reverse micelle assemblies of polymers P1 and P2 with water. UV-visible
absorption spectra of both phases indicate that these polymers fully remain in the apolar
phase (Figure 6.5). While this suggests that the polymers might be kinetically trapped in
the organic phase, it is also possible that these polymers thermodynamically prefer the
apolar phase. To delineate this possibility, these polymers were initially assembled as
micelles in the aqueous phase and equilibrated with toluene (Figure 6.6). The exclusive
presence of these polymers in the aqueous phase, this time, shows that these
supramolecular assemblies are kinetically trapped in the solvent that they are initially
assembled. Overall, these results suggest protein molecules can exchange between phases,
but only remain in the apolar phase if they have favorable interactions with the reverse
micelle interiors.
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Figure 6.5. UV-Vis measurements with reverse micelles of a) polymer P1 (1 × 10-4 M), b)
polymer P2 (1 × 10-4 M starting in toluene (ORG), before and after equilibration with
aqueous phase (AQ).

Figure 6.6. UV-Vis measurements with micelles of a) polymer P1 (1 × 10-4 M), b) polymer
P2 (1 × 10-4 M starting in water (AQ), before and after equilibration with apolar phase
toluene (ORG).
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Following these observations, we were interested in exploring the applicability of this
approach to other non-enzymatic proteins. Green fluorescent protein (GFP) was used as
the first model protein, not only because it can be readily monitored using fluorescence,
but also because the fluorescence itself is a good indicator of whether the protein maintains
its tertiary structure. Since wild-type GFP (pI 6.2) has a net charge of -7 at pH 7.4, we
hypothesized that positively-charged reverse micelles from P2 should be able to move GFP
(-7) from aqueous phase to organic phase. To test this possibility, an aqueous solution of
GFP was equilibrated with the P2 reverse micelle solution in toluene. We were gratified to
find that the emission spectrum of the organic phase clearly showed the presence of GFP.
To further confirm the presence of GFP in the organic phase, samples of both phases were
analyzed by MALDI-MS and a peak with a m/z ratio of 28,432 Da was indeed observed in
both phases (Figure 6.7).

Figure 6.7 MALDI-MS analysis of GFP before and after transportation a) GFP (-7) before
transportation, b) organic phase after transportation GFP (-7) using P1, c) organic phase
after transportation GFP (-7) using P2, d) GFP (+15) before transportation, b) organic phase
after transportation GFP (+15) using P2, c) organic phase after transportation GFP (+15)
using P1.
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Note that the extent of extraction was not optimized to be quantitative, because the
incomplete extraction provides an important insight into the nature of the GFP inside the
reverse micelles. The combination of emission intensities in the aqueous and the organic
phases equal that of the pre-equilibrated emission intensity in the aqueous phase (Figure
6.8a). This observation suggests that GFP maintains its tertiary structure, responsible for
the fluorophore preservation in the protein, during the transport process across the solvent
interface. To confirm that this transport is indeed due to electrostatic complementarity, a
control experiment using the anionic reverse micelle from P1 was carried out. Indeed, there
was no discernible change in the emission intensity of the aqueous phase (Figure 6.8b).

Figure 6.8. Emission spectrum of GFP showing whether it was transported to the organic
phase, a) GFP (-7) transport by P2, b) GFP (-7) transported by P1, c) GFP (+15) transported
by P1, d) GFP (+15) transported by P2.
To further test this idea, we utilized cationic GFP protein, the so-called supercharged GFP
(+15).16 Indeed here, the anionic polymeric reverse micelle from P1 is able to transport the
protein across the interface, while the cationic reverse micelle from P2 does not affect the
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protein in the aqueous phase (Figures 6.8c and 6.8d). The results from these studies show
that: (i) transport of proteins across the interface is due to electrostatic complementarity,
not due to spurious differences in inherent binding abilities of P1 and P2; (ii) the tertiary
structure of the proteins can be preserved upon transport across the interface as indicated
by the roughly equal emission intensities before and after equilibration; (iii) at similar
polymer and protein concentrations, the extent of protein extraction in GFP (+15) is
considerably higher than GFP (-7), showing that binding affinity can influence the extent
of proteins transported across the interface.
6.2.4 Protein transport driven by ligand-protein binding
While electrostatic complementarity can be utilized to simplify protein mixtures and
enable identification of the presence of specific proteins, this ability will be even more
greatly enhanced if proteins can be transported across an interface in response to a specific
ligand-protein interaction. To investigate this possibility, we used bovine carbonic
anhydrase (bCA) as the model protein, because aryl sulfonamides are well-established as
small molecule ligands for this protein.15,18 The design hypothesis here is that if this ligand
was installed in the polymeric reverse micelles, it should be able to selectively transport
bCA to the organic phase due to specific binding.
We designed a zwitterionic amphiphilic polymer for this purpose, as the charge-neutral
zwitterionic

polymer

avoids

any

electrostatics-based

non-specific

interactions.

Accordingly, a random copolymer P3 (Figure 6.9a), containing 40% decyl chain as the
hydrophobic moiety, 40% zwitterionic sulphobetain group as the hydrophilic moiety and
20% benzene sulfonamide as the ligand moiety, was prepared through post-modification
of polymer P1. P3 forms a similarly sized assembly in apolar solvents. To test the capability
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of P3 in transporting proteins, we first labeled bCA with tetramethylrhodamine-5isothiocyanate (TRITC) to monitor the location of proteins using fluorescence. Indeed,
after equilibration of an aqueous phase containing TRITC-bCA with the organic phase
containing P3 micelles, we observed a strong emission peak in organic phase, indicating
the transportation of TRITC-bCA conjugates. Concurrently, there is a dramatic decrease in
the fluorescence intensity in the aqueous phase, indicating bCA is successfully transported
across the interface.
To investigate whether this is driven by the ligand-protein binding, we designed a control
experiment in which a structurally similar amphiphilic polymer, P4, which forms reverse
micelles but lacks the sulfonamide functional group, was equilibrated with an aqueous
solution containing TRITC-bCA. No change is observed in the emission spectrum of both
organic and aqueous phases, when using P4 as the transporter (Figure 6.9b). To further test
whether the specific ligand-protein interaction is responsible for the observed transport
across the interface, we designed another control experiment. For a ligand to bind to the
active site of the protein, the structural integrity of the protein must be maintained. Before
attempting to transport the protein, we disrupted the structure of the protein by denaturing
the protein with acetonitrile and heat. The denatured bCA should not be able to bind the
sulfonamide ligands and thus would not be transported into the organic phase. Indeed, we
find that no fluorescence changes in the aqueous or organic phase are observed, showing
that no bCA was transported into the organic phase (Figure 6.9b). These results confirm
that transportation occurs only when bCA’s native structure is maintained in such a way to
preserve its ability to bind the sulfonamide ligand. Overall, these results suggest that
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specific ligand-protein interactions can be utilized to bind and transport proteins across the
solvent interface.

Figure 6.9. a) Molecular structure of P3, b) Fluorescence change of aqueous/organic phase
using P3 or P4 to transport bCA, c) Molecular structure of P4, d) Fluorescence change of
aqueous/organic phase of P3 to transport bCA, Myb or Lyz, e) MALDI-MS analysis of
protein mixture before and after transportation.
Next, to test the ligand-protein binding based selectivity associated with this process, we
performed another set of control experiments using myoglobin (Mb) and fluorescently
labelled lysozyme (Lyz). Myoglobin was chosen because it has absorption at 409 nm, while
lysozyme was labelled as TRITC-lysozyme conjugates, in order to independently monitor
the movement of these proteins by fluorescence change. Since benzene sulfonamide
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ligands have little to no binding affinity to these proteins, we predicted that Mb and Lyz
would remain in the aqueous phase. Indeed, no discernible fluorescence change was
observed in both aqueous and organic phases for these two proteins, suggesting that the
ligand attached reverse micelles are specific for the target protein bCA (Figure 6.9d). These
experiments were initially done separately due to the possible bleeding of fluorescence
emission. Selective transport from a mixture of these proteins was tested using MS. In this
experiment, Mb, Lyz and bCA were prepared as a protein mixture at the same concentration,
and then P3 was used to transport bCA from the aqueous phase to the organic phase. We
were gratified to find that only bCA is transported to the organic phase, while Mb and Lyz
remained in the aqueous phase as indicated by the mass spectra before and after
equilibration (Figure 6.9e). These data strongly support the idea that ligand-attached
reverse micelle systems are specific for target proteins.

Figure 6.10. Increase in the ligand intensity (z value) can transport more bCA from aqueous
phase to organic phase.
6.3 Summary
In conclusion, we have demonstrated a set of supramolecular assemblies, based on
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amphiphilic polymers, that can transport proteins across a solvent interface. We have
shown here that: (i) simple electrostatic complementarity in polymeric reverse micelle
systems can transport proteins from bulk aqueous phase into the interior of a reverse
micelle assembly in the apolar organic phase; (ii) the activity of the transported proteins is
retained in the process; (iii) the efficiency of protein binding is dependent on the charge
density presented on the protein surface; (iv) the kinetically trapped nature of the
assemblies suggest that the polymers do not ferry the proteins but instead transport likely
occurs during the solvent exchange within the interior of the assembly, when these
assemblies transiently find themselves at the aqueous/organic phase interface during
equilibration, as illustrated in Figure 6.1; (v) specific ligand-receptor interactions can be
used to selectively extract proteins from the aqueous phase. Overall, the most gratifying
finding here is that whole proteins can be moved across a solvent interface into the interior
of a supramolecular assembly, even though the resident location of the assembly is in an
incompatible solvent for the protein. The preliminary findings here have implications in
many areas, especially in sensing, diagnostics, and catalysis. For example, these systems
can be further developed to detect biomarkers in more complex mixtures of proteins.17-23
Similarly, facile incorporation of active proteins in organic solvents could facilitate
enzyme-based catalysis for a broader range of organic substrates.24-29 These constitute
examples of future directions for this research in our own laboratories.
6.4 Experimental procedures
6.4.1 General methods
All reagents were commercially available and used as received unless stated otherwise. 1HNMR spectra were recorded on a 400 MHz or a 500 MHz NMR spectrometer using residual
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proton resonance of the solvents as internal standard. Chemical shifts are reported in parts
per million (ppm). Mass spectra were obtained by a Bruker AmaZon quadrupole ion trap
mass spectrometer coupled with electrospray ionization source. Gel permeation
chromatography (GPC) was used to estimate the molecular weight of polymers using
THF/DMF as eluent and 1 μL of toluene was added as the internal reference. Polystyrene
standards were used for calibration and data analysis.
For the DLS measurements, the polymers were dissolved in toluene, and one equivalent of
water per hydrophilic unit was added to form the water pool inside the reverse micelles.
The samples were sonicated until clear solutions were formed. DLS measurements were
carried out in a quartz cuvette at room temperature. The sizes of each solution were
recorded overtime by a Malvern Nanozetasizer ZS90 with a 637-nm laser source with noninvasive backscattering technology detected at 173o using quartz cuvette. Standard
operating procedures (SOP) are set up including following parameters: the sample was
equilibrated for 120 s at 25 oC before each measurement; the sizes were reported as the
hydrodynamic diameter (DH) and each measurement average 16 runs were repeated three
times.
For TEM measurement, the same sample for DLS measurement was dropped onto carboncoated copper grid. The grid was dried by slow evaporation in air, and then dry separately
in a vacuum overnight. Images were recorded on a JEOL-2000FX electron microscopy
operated at 200 kV and at a nominal magnification of 5000X. At least 10 locations on the
TEM grid were examined. The assembly diameter was calculated using ImageJ software.
Matrix Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS): MALDIMS analysis of samples before and after transport were performed with Bruker Autoflex
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III time-of-flight mass spectrometer. The matrix was prepared with a solvent mixture of
acetonitrile, water and trifluoroacetic acid (with a ratio 50:47.5:2.5) containing 10 mg/mL
sinapic acid. The matrix and samples from aqueous or organic phase were mixed at 1:1
ratio and spotted on the MALDI target for analysis.
Protein transport and release experiments: For protein transport with reverse micelles, 500
uL of a toluene solution of polymers (1 mg/mL) with 1 mL of protein in 10 mM PBS buffer
at pH 7.4. The mixture is vortexed for 30 min and centrifuged at 10,000 rpm for 1 h to
separate the organic and aqueous layers. The organic phase and aqueous phase is then
analyzed by MALDI-MS or fluorimeter.
For the release of proteins back into the aqueous phase, the 500 uL organic phase contains
proteins was treated with 100 uL THF and then equilibrated with 400 uL 1 M HCl for 30
minutes. After centrifugation for 30 minutes, the phase was separated. The pH of aqueous
phase was adjusted to 7.4 for further analysis.
Quantification of porcine liver esterase in reverse micelles: 1) Through the BCA method:
The standard curve was made using Pierce BCA assay kitS3 as following the protocols.
Pipette 0.1 mL of each standard sample (0.005, 0.025, 0.05, 0.125, 0.25, mg/mL, three
replicates for each sample) and the unknown plE sample into test tube and then add 2.0 mL
of the working reagent to each tube and mix well. Cover and incubate tubes at 60 oC for 30
minutes and then cooled to room temperature. Then took the readings from UV-Vis at 562
nm. The standard curve was prepared plotting the average 562 nm measurement for each
standard sample vs. its concentration. Then the plE concentration of aqueous phase after
transport was determined using the standard curve. The difference of aqueous phase before
and after the equilibration provide the loading capacity of reverse micelles.
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2) Through SDS-PAGE method: Standard curves were generated from the known
concentrations of protein samples loaded into the gel lanes. Then the samples of aqueous
phase before and after the equilibration were loaded to the gel lane. For the organic phase,
the samples for gel lanes were dried with air and dissolved in THF/H2O. The intensities for
the band will be used to calculate the protein concentration of each phase. The
concentration of protein for the organic phase after equilibration can provide how much
proteins have been transported into the organic phase.
SDS-PAGE Analysis: For the transport and release of plE studies: 20 µL of different
samples containing plE were mixed with 20 µL of loading buffer (3% DTT), then incubated
95 ºC for 10 minutes before subjecting 10 µL of each sample to acrylamide gel
electrophoresis. Standard curves were generated from the known concentrations of pure
protein samples loaded into the gel lanes. The gel image analysis and quantification were
performed with Bio-Rad Image LabTM software.
Evaluation of PlE activity in reverse micelles: First, the amount of plE that got transported
into the organic phase was calculated based on the SDS-PAGE or BCA assay. The organic
phase containing plE was then equilibrated with an aqueous phase of substrate S1 (100 µM)
for 30 minutes. After centrifugation for 30 minutes, the fluorescence of aqueous phase was
measured over time. The control experiments with the same amount of plE were performed
in aqueous phase.
Protein denaturation: bCA was dissolved in 10 mM PBS (pH 7.4) buffer at a concentration
of 1mg/mL, 10% by volume of acetonitrile was added to the solution and stirred at room
temperature for 10 minutes. After that, the mixture was heated at 100oC for 2 minutes and
then a buffer exchange was performed using 3 k Da Amicon Ultra Centrifugal Filters to
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remove acetonitrile. Then the sample was diluted to 0.1 mg/mL in 10 mM PBS (pH 7.4)
for CD measurement.
Circular dichroism (CD) spectra: CD spectra bCA and denatured bCA were recorded on
JASCO J-1500 spectrophotometer. For recording the spectra, 200 µL 0.1 mg/mL protein
solution was injected into a quartz cuvette of 1-mm path length, equilibrated at 25 ºC for
10 min and scanned from 190 to 250 nm (scan rate: 20 nm/min, interval: 0.2 nm, average
of three spectra).
Fluorescent labeling proteins: Labeling of proteins (lysozyme (Lyz), bovine serum albumin
(BSA) and bovine carbonic anhydrase (bCA)) with Tetramethylrhodamine-5Isothiocyanate (TRITC) or Fluorescein Isothiocyanate (FITC). In a typical labelling
procedure, proteins (4 mg) were dissolved separately in 2 mL of 0.1 M NaHCO3 buffer
(pH 8.5) and stirred for 15 min at 4 ºC. TRITC/FITC (5 eq. of each protein, 10 mg/mL in
DMSO) was added dropwise to each protein solution and stirred at 4 ºC for 2 h protected
from light. The labelled-proteins were purified by extensive dialysis with 50 mM PBS pH
7.4 and 50 mM NaCl mixture to remove excess dye and concentrated using 3 kDa Amicon
Ultra Centrifugal Filters. Protein concentrations in each labelled conjugate were calculated
using UV-Vis spectroscopy.
6.4.2 Polymer synthesis
Synthesis of compound 1: According to previous procedureS1, to a solution of acetone
mixed with K2CO3 (11.84 g, 85.65 mmol) and 18-crown-6 (1.13 g, 4.28 mmol), 4hydroxybenzaldehyde (5.23 g, 42.83 mmol) was added and stirred for 5 min. To this
mixture, 1-bromodecane (14.21 g, 64.24 mmol) was added and stirred while refluxing for
20 h. The reaction mixture was then cooled to room temperature and filtered to afford the
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crude product in acetone solution. The solvent was evaporated to dryness and purified by
silica gel column chromatography (8-10% ethyl acetate in hexanes) to obtain 8.8 g (79%
yield) of 1. 1H NMR (400 MHz, CDCl3) δ 9.80 (s, 1H), δ 7.83-7.81 (d, J = 8.0 Hz, 2H), δ
7.00-6.98 (d, J = 8.0 Hz, 2H), δ 4.02-4.05 (t, J = 6.6 Hz, 2H), δ 1.76-1.83 (quint, 2H), δ
1.47-1.26 (m, 14H), δ 0.87-0.91 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 190.7,
164.2, 131.9, 129.7, 114.7, 68.4, 31.9, 29.5, 29.63, 29.32, 29.31, 29.1, 25.9, 22.7, 14.1.
ESI-MS (expected: [m+H]+= 263.19, obtained: [m+Na]+= 285.2)
Scheme 6.2. Synthetic route for polymer P1
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Synthesis of compound 2: Methyltriphenylphosphonium bromide (6.58 g, 25.11 mmol)
and potassium tert-butoxide (3.94 g, 35.15 mmol) were mixed in a round bottom flask, and
dry THF (20 mL) was added to the mixture. The mixture was stirred under argon
atmosphere in an ice bath for 15 min to yield a bright yellow solution. 1 (6.58 g, 25.11
mmol) was slowly added to the mixture. The reaction mixture was further stirred for 5 h.
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After the reaction, saline and ethyl acetate were added for extraction. The combined
organic layer was separated and washed with saline (3 times). The organic layer was
evaporated to dryness and purified by silica gel column chromatography (3-5% ethyl
acetate in hexanes) to afford 5.7 g (88% yield) of 2. 1H NMR (400 MHz, CDCl3) δ 7.317.33 (d, J = 8.0 Hz, 2H), δ 6.83-6.85 (d, J = 3.4 Hz, 2H), δ 6.61-6.68 (q, 1H), δ 5.57-5.61
(d, J = 7.2 Hz, 1H), δ 5.09-5.12 (d, J = 4.4 Hz, 1H), δ 3.93-3.96 (t, J = 5.4 Hz, 3H), δ
1.73-1.80 (quint, 2H), δ 1.27-1.46 (m, 14H), δ 0.86-0.89 (t, J = 6.8 Hz, 3H). 13C NMR (125
MHz, CDCl3) δ 159.1, 136.4, 130.3, 127.4, 114.6, 111.5, 68.1, 32.1, 29.7, 29.7, 29.5, 29.4,
29.4, 26.1, 22.8, 14.2. ESI-MS (expected: [m+H]+= 261.21, obtained: [m+Na]+= 283.2).
Scheme 6.3. Synthetic route for polymer P2, P3 and P4

Synthesis of compound 3: To a solution of acetone mixed with K2CO3 (6.79 g, 49.13 mmol),
NaI (7.36 g, 49.13 mmol) and 18-crown-6 (0.65 g, 2.46 mmol), 4-hydroxybenzaldehyde
(3.00 g, 24.57 mmol) was added and stirred for 5 min. To this mixture, tert-butyl
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bromoacetate (9.58 g, 49.13 mmol) was added and stirred while refluxing for 20 h. The
reaction mixture was then cooled to room temperature and filtered to afford the crude
product in acetone solution. The solvent was evaporated to dryness and purified by silica
gel column chromatography (10-13% ethyl acetate in hexanes) to obtain 5.3 g (91% yield)
of 3. 1H NMR (400MHz, CDCl3) δ 9.88 (s, 1H), δ 7.82-7.84 (d, J = 4.2 Hz, 2H), δ 6.976.99 (d, J = 4.4 Hz, 2H), δ 4.59 (s, 2H), δ 1.47 (s, 9H). 13C NMR (100 MHz, CDCl3) δ
190.8, 167.2, 162.8, 132.0, 130.7, 114.9, 83.0, 65.6, 28.1. ESI-MS (expected: [m+H]+=
237.1, obtained: [m+Na]+= 259.1)
Synthesis of compound 4: Methyltriphenylphosphonium bromide (7.94 g, 22.24 mmol)
and potassium tert-butoxide (2.50 g, 22.24 mmol) were mixed in a round bottom flask, and
dry THF (15 mL) was added to the mixture. The mixture was stirred under argon
atmosphere in an ice bath for 15 min to yield the bright yellow solution. 3 (3.5 g, 14.83
mmol) was slowly added to the mixture. The reaction mixture was further stirred for 5 h.
After the reaction, saline and ethyl acetate were added for extraction. The combined
organic layer was separated and washed with saline (3 times). The organic layer was
evaporated to dryness and purified by silica gel column chromatography (3-5% ethyl
acetate in hexanes) to afford 3.3 g (95% yield) of 4. 1H NMR (400MHz, CDCl3) δ 7.337.35 (d, J = 1.0 Hz, 2H), δ 6.84-6.87 (d, J = 1.0 Hz, 2H), δ 6.63-6.68 (dd, J = 17.6, 10.9
Hz, 1H), δ 5.60-5.64 (dd, J = 17.6, 0.9 Hz, 1H), δ 5.13-5.15 (dd, J = 10.9, 0.8 Hz,), δ 4.51
(s, 2H), δ 1.49 (s, 9H). 13C NMR (100MHz, CDCl3) δ 168.0, δ 157.7, δ 136.2, δ 131.3, δ
127.48, δ 114.7, δ 112.1, δ 82.4, δ 65.8, δ 28.1. ESI-MS (expected: [m+H]+= 235.1,
obtained: [m+Na]+= 257.1)
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Synthesis of random copolymer 5: A mixture of the compound 1 (500 mg, 1.92 mmol), 2
(675 mg, 2.88 mmol) and N-tert-butyl-N-(2-methyl-1-phenylpropyl)-O-(1-phenylethyl)
hydroxylamine (NMP initiator, 25 mg, 0.077 mmol) were degassed by three freeze/thaw
cycles, sealed under argon, and heated at 120 oC under argon for 12 h. After the reaction
cooled down to room temperature, the reaction mixture was dissolved in minimal amount
of DCM, and precipitated 3 times in MeOH. The precipitate was collected and dried under
vacuum to yield 988 mg (84% yield) of 5. GPC (THF): Mn= 11 K Da, Đ= 1.09. 1H NMR
(400MHz, CDCl3) δ 6.59-6.25, 4.42, 3.85, 1.75, 1.48-1.21, 0.88. From 1H NMR,
integration of methylene proton next to the phenol in both alkyl unit (f) and carboxylate
unit (g) provided the molar ratio of monomers to be 4:6 (decyl/carboxylate).

Synthesis of random copolymer P1: Dichloromethane (2 mL) was added to dissolve the
dried random copolymer P1 (200 mg). Trifluoroacetic acid (0.5 mL) was added to the
mixture and stirred for 12 h at room temperature. The reaction mixture was evaporated and
dried under vacuum to obtain P1 (95% yield). 1H NMR (400MHz, CDCl3) δ 6.59, 4.65,
3.90, 1.75, 1.48-1.21, 0.88. 13C NMR (100MHz, CDCl3) δ 174.2, 156.6, 154.8, 128.7, 114.2,
68.1, 65.1, 39.9, 31.9, 29.6, 29.3, 26.1, 22.7, 14.1. GPC (DMF): Mn= 11 K Da, Đ= 1.12.
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From 1H NMR, a sharp decrease in integration at δ 1.48 suggested the successful
deprotection of tert-butyl group. From 1H NMR, integration of proton a and f again
confirmed the molar ratio of monomers to be 4:6 (decyl/carboxylate)

Synthesis of random copolymer 6: Carboxylate polymer P1 (100 mg, 0.22 mmol
carboxylic acid repeat unit) and N-Hydroxysuccinimide (38 mg, 0.33 mmol) was weighed
in a 20 mL glass vial and dissolved in 5 mL dry THF and stirred at 0 oC. N-(3Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) (63 mg, 0.33 mmol)
was added to the mixture and stirred for 4 hours. Afterwards, triethylamine (92 uL, 0.66
mmol) and N, N-dimethylethylenediamine (29 mg, 0.33 mmol) were added dropwise to
the reaction mixture and the solution was stirred for 24 h at room temperature. After that,
the modified polymer was purified by dialyzing against dichloromethane/methanol using
a membrane of MWCO: 3.5 kDa. After dialysis, the solvent was evaporated and the
polymer was dried under vacuum for 24 h. Yield: 90%, GPC (THF) Mn: 12 K. Đ: 1.15. 1H
NMR (400 MHz, CDCl3): δ 7.15, 6.57-6.2, 4.39, 3.84, 3.42, 2.44, 2.22, 1.74, 1.43-1.26,
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0.88. From 1H NMR, integration of proton a and e again confirmed the molar ratio of these
two monomers to be 4:6.

Synthesis of random copolymer P2: Random copolymer 6 (80 mg, 0.16 mmol tertiary
amine repeat unit) was weighed in a 20 mL glass vial and dissolved in 5 mL dry THF and
stirred at 0 oC under argon protection. Methyl trifluoromethanesulfonate (56 mg, 0.33
mmol) was added to the solution dropwise and stirred for 2 hours. Afterwards, the solvent
was evaporated and the polymer was dried under vacuum for 24 h. Yield: 90%, GPC (THF)
Mn: 12 K. Đ: 1.15. 1H NMR (400 MHz, acetone-d6): δ 8.24, 6.7-6.3, 4.49, 3.92, 3.77, 3.40,
1.78, 1.48-1.26, 0.88. 13C NMR (100 MHz, CDCl3) δ 173.5, 156.6, 122.7, 53.5, 49.8, 31.9,
29.6, 29.35, 29.33, 26.1, 22.7, 14.1. From 1H NMR, proton peak of e shifting downfield
suggested the successful conversion of tertiary amine to quaternary ammonium. Ratios of
two monomers were calculated based on integration of a and h.
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Synthesis of random copolymer 7: P1 (100 mg, 0.22 mmol carboxylic acid repeat unit) and
N-hydroxysuccinimide (38 mg, 0.33 mmol) was dissolved in 5 mL dry THF and stirred at
0 oC. EDC (63 mg, 0.33 mmol) was added and stirred for 4 hours. Afterwards, triethylamine
(92 uL, 0.66 mmol) was added and stirred for 30 minutes. Then a mixture of 4-(2aminoethyl) benzenesulfonamide (22 mg, 0.11 mmol) and N, N-dimethylethylenediamine
(19.3 mg, 0.22 mmol) in 1 mL DMF were added dropwise and the solution was stirred for
24

h

at

room

temperature.

After
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that,

the

modified

polymer

was

purified by dialyzing against DCM/methanol using a membrane of MWCO: 3.5 kDa. After
dialysis, the solvent was evaporated and the polymer was dried under vacuum for 24 h.
Yield: 93%, GPC (THF) Mn: 12 K. Đ: 1.2. 1H NMR (400 MHz, CDCl3): δ 7.82, 7.15, 6.576.2, 4.56-4.2, 3.87-3.78, 3.42, 2.44, 2.22, 1.74, 1.43-1.26, 0.88. Ratios of three components
were calculated based on integration of a, e and m.
Synthesis of random copolymer P3: Random copolymer 7 (80 mg, 0.09 mmol tertiary
amine repeat unit) was dissolved in 5 mL dry THF, 1,3-propane sultone (39 uL, 0.45 mmol)
was added to the solution and the mixture was refluxed at 80 oC overinight. Then the
modified polymer was purified by dialyzing against aacetone using a membrane of MWCO:
3.5 kDa. After dialysis, the solvent was evaporated and the polymer was dried under
vacuum for 24 h. Yield: 95%, GPC (DMF) Mn: 12 K. Đ: 1.2. 1H NMR (400 MHz, CDCl3):
δ 7.8, 7.15, 6.57-6.2, 4.52-4.2, 4.05-3.42, 2.78, 1.98, 1.74, 1.43-1.26, 0.88. 13C NMR (100
MHz, CDCl3) δ 181.6, 172.8, 170.4, 156.3, 128.8, 114.2, 100.5, 67.9 43.4, 39.6, 31.9, 29.6,
29.3, 26.15, 26.13, 22.7, 14.1. Ratios of three components were calculated based on
copolymer 7.
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Synthesis of random copolymer P4: Random copolymer 6 (80 mg, 0.16 mmol tertiary
amine repeat unit) was dissolved in 5 mL dry THF, 1,3-propane sultone (71 uL, 0.80 mmol)
was added to the solution and the mixture was refluxed at 80 oC overinight. Then the
modified polymer was purified by dialyzing against aacetone using a membrane of MWCO:
3.5 kDa. After dialysis, the solvent was evaporated and the polymer was dried under
vacuum for 24 h. Yield: 95%, GPC (DMF) Mn: 11 K. Đ: 1.1. 1H NMR (400 MHz, CDCl3):
δ 8.30, 6.2-6.61, 4.64−4.29, 3.97-2.65, 1.76, 1.54-1.1, 0.87. 13C NMR (100 MHz, CDCl3)
δ 170.7, 157.8, 129.0, 114.8, 107.9, 68.2, 50.9, 42.8, 31.9, 29.6, 29.3, 26.2, 22.7, 14.1.
Ratios of two components were calculated based on polymer P1.

Synthesis of substrate S1: Compound 8 and 9 were synthesized according to previous
reported procedures.S2 The mixture of compound 8 (1.0 eq), compound 9 (2 eq),
CuSO4.5H2O (0.5 equiv.) and sodium ascorbate (0.5 eq.) in MeOH/H2O (1:1) solvent
mixture was heated at 50 oC for 24 h. The reaction progress was monitored by TLC. After
completion of the reaction, the reaction mixture was partitioned between ethyl acetate and
saturated aqueous NH4Cl solution. The aqueous layer was extracted twice with ethyl
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acetate and the combined organic layer was dried over Na2SO4 and evaporated to dryness.
The crude product was purified by silica gel column chromatography. Yield: 93%, 1H
NMR (400 MHz, CDCl3) δ 7.61 (s, 1H), δ 7.53 (d, J = 4.4 Hz, 1H), δ 6.95 (m, 2H), δ 6.616.52 (m, 2H), δ 6.18 (s, 1H), δ 5.80 (s, 2H), δ 5.15 (s, 2H), 4.32 (t, J = 3.6 Hz, 2H), δ 4.12
(t, J = 4.8 Hz, 2H), δ 3.85 (t, J = 4.6 Hz, 2H), δ 3.75-3.62 (m, 26H), δ 3.55 (m, 2H), δ 3.36
(s, 3H), δ 3.10 (s, 3H), δ 2.95 (s, 3H), δ 2.4 (m, 4H), δ 1.92 (m, 2H), δ 1.65 (m, 4H), δ 1.35
(m, 2H); 13C NMR (100 MHz, CDCl3) δ 171.9, 160.9, 160.0, 159.4, 159.2, 154.9, 152.3,
138.4, 125.9, 115.2, 113.2, 113.0, 106.2, 106.0, 103.4, 84.8, 71.9, 70.8, 70.6, 70.58, 70.50,
69.6, 59.1, 40.1, 35.4, 33.7, 29.3, 26.2, 23.9, 18.7. HR-ESI-MS (calculated: [m+H]+=
931.45, obtained: [m+Na]+= 953.3553).
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CHAPTER 7
ENZYME NANOREACTOR FOR CATALYSIS IN APOLAR SOLVENT
7.1 Introduction
Despite many decades of research to match the catalytic fidelity of nature’s
macromolecules, enzymes still remain the hallmark of excellence for activity, selectivity,
and turnover numbers.1,2 Nature had billion years of evolutionary pressure as the driving
force to arrive at these efficient catalysts. Achieving such fidelity, using synthetic
molecules, on a reasonable human time scale is difficult.3–7 Therefore, it is useful to capture
the essence of biological catalysts themselves in abiological processes. This goal is
complicated by the fact that practical utility of enzymes is quite limited in most abiological
processes, because these catalysts are evolved to only operate in their native environment.8–
11

Endowing proteins with the ability to operate in non-native environments is clearly a

challenge, which has been recognized for several decades.12–14 A promising solution to this
challenge would involve the ability to encapsulate proteins in a compatible local nanoenvironment, although the global environment of the reaction media might be incompatible
with the protein.15–18 Although this is easy to imagine, implementation of such a possibility
is cumbersome, because this requires proteins to be transported across the incompatible
solvent interface.
Reverse micelles or water-in-oil microemulsions, stabilized by amphiphilic molecules,
can form the basis for distributing enzymes in apolar organic solvents.19–24 In this approach,
the enzymes can be directly encapsulated inside without the need of any functional group
modification. With the presence of surfactants at the interface of water and organic solvents,
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enzymes are protected against potential denaturation by the bulk organic solvents. This
scenario allows for organic substrate molecules to be conveniently distributed in the bulk
solvent. We have shown a simple polymeric platform that selectively transports watersoluble proteins from an aqueous phase to the water-pool of a reverse micelle in an apolar
organic phase based on complementary electrostatic interactions or specific ligand-protein
binding interactions.25 Such a capability provides a great opportunity for performing and
modulating enzymatic catalysts in organic solvents. Controlling substrate accessibility to
the core of the nanoreactor can expand the system to function in a more complex
environment, where a mixture of substrates is present. In this chapter, we will build enzyme
nanoreactors for catalysis in apolar solvent, and then introduce crosslinks in the molecular
assemblies to control substrate permeability into the assembly to engineer unnatural
selectivity in enzymes that are known to be inherently promiscuous in substrate selectivity
(Figure 7.1).

Figure 7.1. Schematic representation of enzyme nanoreactor in organic phase and introduce
unnatural substrate selectivity to the enzymes for catalysis in apolar solvent.
7.2 Results and discussion
7.2.1 Molecular design and synthesis
We are interested in engineering the reverse micelle scaffold to introduce new substrate
selectivity in enzymes, which are known to be inherently promiscuous. We hypothesize
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that crosslinking the reverse micelles in the organic phase would affect the substrate
permeability into this aggregate, which should introduce size-based selectivity. For this
purpose, we propose a polymer design, achieved using nitroxide-mediated polymerization,
comprises of 50% p-decyloxystyrene as the hydrophobic monomer and 50% of Nmethylpyridyldisulfide-styrene as the hydrophilic monomer. The hydrophilic side chain
functionalities also can be readily crosslinked in presence of dithiolthreitol (DTT). The
polymer was prepared following scheme 7.1.
Scheme 7.1 Synthesis route for target polymer
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7.2.2 Reverse micelle preparation and characterization

Figure 7.2. a) DLS profile of target polymer in DCM at 1 mg/mL; b) TEM images of
reverse micelle solutions.
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We firstly tested whether this polymer would self-assemble in apolar solvent. By
distributing it in different organic solvents such as toluene, dichloromethane, chloroform
and ethylacetate at a concentration of 1 mg/mL (2 eq. water per charged group), we have
observed aggregate formation in DCM and chloroform. Assemblies with a fairly
homogeneous size distribution of 500 nm was found for designed polymer, as discerned by
both dynamic light scattering (DLS) (Figure 7.2a) and transmission electron microscopy
(TEM) (Figure 7.2b). The water molecules are added here to provide a ‘water pool’ for the
reverse micelles, which is quite critical for the enzyme entrapment and retainment of
enzyme activity in the following experiments. Therefore, we have tried to vary the water
content of the reverse micelle assemblies from 0.5 uL to 5 uL per mL reverse micelle
solution. We have figured out that if water is more than 2 uL per mL reverse micelle
solution, the assemblies were no longer stable because we didn’t see a peak from DLS.
Only when water addition is lower than 2 uL/mL could we see peaks from DLS. Also, with
the increasing amount of water, the size of reverse micelles also increased (Figure 7.3).

Figure 7.3. DLS profiles for reverse micelles with varied amount of water added.
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Next, we are curious to see whether we could crosslink the reverse micelles and control
the crosslinking density. In addition to increasing thermodynamic stability to the reverse
micelle assemblies, this process should also offer selective permeability of substrate
molecules. For this purpose, we added different amount of DTT to induce the disulfide
crosslinking. As shown in Figure 7.4, we firstly quantified the maximum amount of the
PDS group in 1 mg/ml polymer solution based on the absorbance of cleaved PDS at 350
nm. Then varied amount of DTT from 0.1 eq. to 0.3 eq. of PDS group was added to the
reverse micelle solution to get desired crosslinking density (Figure 7.4).
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Figure 7.4 Crosslinking of reverse micelles with varied amount of DTT
7.2.3 Enzyme encapsulation and quantification
We envisaged that our reverse micelles would bind to complementarily charged proteins
in the aqueous phase and ferry them over to the organic phase and remain active based on
our previous findings. To test this possibility, we used GFP as the model protein because
we can easily monitor the encapsulation and speculate their structural integrity using
fluorescence. As shown in Figure 7.5a, with increased polymer concentration from 0.25
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mg/mL to 1 mg/mL, we observed increased encapsulation in organic phase, suggested from
the increase in fluorescence signal of GFP.
We were then excited to test this system with an enzymatic protein, porcine liver esterase
(plE), which would be the model enzyme to build nanoreactor due to its catalytic efficiency
in a variety of ester substrates. To monitor and quantify the enzyme encapsulation by
reverse micelles, we labeled plE with a fluorescent dye, Cy3. Herein we have tried two
different approaches for enzyme encapsulation: 1) liquid-liquid extraction between reverse
micelle in DCM and enzyme solution in PBS buffer; 2) directly add 1uL of plE aqueous
solution into the organic phase and sonicate. We found that two approaches offered same
loading capacity based on the same polymer concentration. The loading capacity for
1mg/mL polymer was found to be 2.75 nM.

Figure 7.5. a) GFP encapsulation by reverse micelles with varied concentration; b) Cy3
labeled plE encapsulation in reverse micelles through extraction approach (blue) or
sonication approach (orange).
7.3 Summary and future directions
In this chapter, we have investigated the use of amphiphilic polymer based reverse
micelles to transport enzymes across an immiscible solvent interface in order to perform
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enzymatic catalysis in organic solvents. Using random cationic amphiphilic polymer, we
have shown the preparation of reverse micelles, enzyme encapsulation in apolar solvent
and controlled crosslinking density of these nanoassemblies. We found that the micelle size
can be tuned by the amount of water added. Crosslinking of reverse micelles from the
hydrophilic core can be achieved using disulfide chemistry but the DTT might affect the
protein activity in the following studies. Future work will need to use different crosslinking
chemistry to minimize the implications in the encapsulated enzyme. Also, studying the
enzyme catalysis over a range of different substrates will be done to figure out whether
there can be a threshold for the molecules to diffuse into the reactor.
7.4 Experimental procedures
7.4.1 General methods
All reagents were commercially available and used as received unless stated otherwise. 1HNMR spectra were recorded on a 400 MHz or a 500 MHz NMR spectrometer using residual
proton resonance of the solvents as internal standard. Chemical shifts are reported in parts
per million (ppm). Mass spectra were obtained by a Bruker AmaZon quadrupole ion trap
mass spectrometer coupled with electrospray ionization source. Gel permeation
chromatography (GPC) was used to estimate the molecular weight of polymers using
THF/DMF as eluent and 1 μL of toluene was added as the internal reference. Polystyrene
standards were used for calibration and data analysis.
Dynamic Light Scattering (DLS): For the DLS measurements, the polymers were dissolved
in toluene/dichromethane/chloroform, and two equivalent of water per hydrophilic unit
was added to form the water pool inside the reverse micelles. The samples were sonicated
until clear solutions were formed. DLS measurements were carried out in a quartz cuvette
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at room temperature. The sizes of each solution were recorded overtime by a Malvern
Nanozetasizer ZS90.
Transmission Electron Microscope (TEM): The same sample for DLS measurement was
dropped onto carbon-coated copper grid. The grid was dried by slow evaporation in air
overnight. Images were recorded on a JEOL-2000FX electron microscopy operated at
200 kV and at a nominal magnification of 5000X. At least 10 locations on the TEM grid
were examined. The assembly diameter was calculated using ImageJ software.
Protein encapsulation by reverse micelles: 600 uL of a DCM solution of polymers (1
mg/mL) with 200 uL of enzyme in 10 mM PBS buffer at pH 7.4. The mixture is vortexed
for 30 min and centrifuged at 10,000 rpm for 1 h to separate the organic and aqueous layers.
The organic phase and aqueous phase are then separated for analysis.
Evaluation of PlE activity in reverse micelles: First, the amount of plE that got transported
into the organic phase was calculated based on the SDS-PAGE or BCA assay. The organic
phase containing plE was then equilibrated with an aqueous phase of substrate S1 (100 µM)
for 30 minutes. After centrifugation for 30 minutes, the fluorescence of aqueous phase was
measured over time. The control experiments with the same amount of plE were performed
in aqueous phase.
7.4.2 Synthesis
Synthesis of molecule 2: Methyltriphenylphosphonium bromide (7.94 g, 22.24 mmol) and
potassium tert-butoxide (2.50 g, 22.24 mmol) were mixed in a round bottom flask, and dry
THF (30 mL) was added to the mixture. The mixture was stirred under argon atmosphere
in an ice bath for 15 min to yield the bright yellow solution. Molecule 1 (2.2 g, 14.83 mmol)
was slowly added to the mixture. The reaction mixture was further stirred overnight. After
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the reaction, THF was evaporated, saline and ethyl acetate were then added for extraction.
The organic layer was washed with saline (3 times) and then evaporated to dryness and
purified by silica gel column chromatography (3-5% ethyl acetate in hexanes) to afford 1.3
g (65% yield) of 2. 1H NMR (400MHz, CDCl3) δ 7.97-7.99 (d, J = 8.0 Hz, 2H), δ 7.467.44 (d, J =8 Hz, 2H), δ 6.78-6.71 (dd, J = 11.2, 11.2 Hz,), δ 5.88-5.84 (d, J =16 Hz, 1H),
δ 5.40-5.37 (d, J =12 Hz, 1H). ESI-MS (expected: [m+H]+= 149.05, obtained: [m+Na]+=
171.1)
Scheme 7.2 Synthesis route for monomers and target polymer

Synthesis of molecule 3: Molecule 2 (1.3 g, 8.7 mmol), SOCl2 (1.2g, 10.4 mmol) and THF
(20 mL) were kept under reflux for overnight. The mixture was then evaporated to dryness
and redissolved in fresh and dry THF (20 mL). 2-Hydroxyethylpyridyldisulfide (1.63g, 8.7
mmol) and triethylamine (1.77g, 17.4 mmol) with 5mL THF was then added to this solution
and stirred at room temperature for 12 hours. Solvent was evaporated and the residue was
further purified by silica gel column chromatography (3-5% ethyl acetate in hexanes) to
146

afford 2.2 g (83% yield) of 3. 1H NMR (400 MHz, CDCl3) δ 8.45-8.44 (d, J = 4.0 Hz, 1H)
7.97-7.99 (d, J = 8.0 Hz, 2H), δ 7.70-7.68 (d, J = 8.0 Hz, 1H), δ 7.58-7.53 (m, 1H), δ 7.467.44 (d, J =8 Hz, 2H), δ 7.07-7.04 (m, 1H), δ 6.78-6.71 (dd, J = 11.2, 11.2 Hz,), δ 5.885.84 (d, J =16 Hz, 1H), δ 5.40-5.37 (d, J =12 Hz, 1H), δ 4.56 (t, 2H), δ 3.18 (t, 2H). ESIMS (expected: [m+H]+= 318.05, obtained: [m+Na]+= 340.13)
Synthesis of polymer P0: A mixture of the compound 3 (610 mg, 1.92 mmol), 4 (499 mg,
1.92 mmol) and N-tert-butyl-N-(2-methyl-1-phenylpropyl)-O-(1-phenylethyl)hydroxyl
amine (NMP initiator, 25 mg, 0.077 mmol) were degassed by three freeze/thaw cycles,
sealed under argon and heated at 120 oC for 10 h. After the reaction cooled down to room
temperature, the reaction mixture was dissolved in minimal amount of DCM and
precipitated 3 times in MeOH. The precipitate was collected and dried under vacuum to
yield 1045 mg (95% yield) of 5. GPC (THF): Mn= 14.5 K Da, Đ= 1.09. 1H NMR (400

MHz, CDCl3) δ 8.43, 7.69, 7.55, 7.04, 6.56, 4.54, 3.86, 3.17, 1.74-1.21, 0.88. From 1H
NMR, integration of peak at δ 4.54 and peak at δ 3.86 provided the molar ratio of monomers
to be 1:1 (decyl/PDS).
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Synthesis of polymer P1: Random copolymer P0 (200 mg, 0.35 mmol PDS repeat unit)
was weighed in a 20 mL glass vial and dissolved in 5 mL dry dichoromethane and stirred
at 0 oC under argon protection. Methyl trifluoromethanesulfonate (118 mg, 0.7 mmol) was
added to the solution dropwise and stirred for 2 hours. Afterwards, the solvent was
evaporated, the polymer was dried under vacuum for 24 h. Yield: 90%, GPC (THF) Mn:
15 K. Đ: 1.15. 1H NMR (400 MHz, acetone-d6): δ 9.03, 8.77, 8.54, 7.93, 7.76, 6.71, 4.67,
4.66, 3.94, 3.52, 3.40, 1.78-1.26, 0.88. From 1H NMR, proton peak of δ 4.46 suggested the
successful conversion of tertiary amine to quaternary ammonium.
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CHAPTER 8
SUMMARY AND FUTURE DIRECTIONS
8.1 Summary of the dissertation
Through the use of modern synthetic organic chemistry, we have built interesting, novel
and smart Nanoassemblies with tunable responses and potential applications such as
sensing, diagnostics and drug delivery. We have synthesized a variety of amphiphiles to
understand the structural factors that program molecules to self-assemble into functional
materials. Furthermore, by addressing the design challenge to prepare smart materials with
desired functionalities, controlled molecular weight and the ability to respond to a broad
range of stimuli, we have developed different applications based on these materials.
The primary challenge for design of novel stimuli-responsive materials concerns stimulus
and response. In chapter 2, taking different stimulus as inputs and response as outputs, I
successfully achieved logic control over the designed materials. Notably, a combination of
an intrinsic trigger and an extrinsic trigger was introduced to this system for the first time.
A photocaged ligand activation method was designed that nanoassembly would
disassemble only to the concurrent presence of two inputs (AND gate). Similarly,
molecular designs for OR gate and NOT gate were also developed and demonstrated. This
set of materials offer the possibility of substantially increasing specificity in responses,
which could find use in many applications, including drug delivery and diagnostics.
Enzyme as a stimulus to trigger the response of nanomaterials is an exciting finding from
our group and has shown great potential for developing rapid response materials for sensing.
In chapter 3, rrom the chemistry perspective, I have a strong desire to dig the structural
factors that tailor the molecules to self-assemble into enzyme responsive materials. By
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synthesizing two series of 12 new oligomers with varied structures, I systematically
investigated how molecular weight and hydrophilic-hydrophobic balance affects the
materials’ response towards enzyme. The fundamental insights generated from these
findings are impacting the new materials design in our group and will also benefit areas of
enzyme-sensitive materials.
In chapter 4, I designed a self-immolative nanogel platform based on block-copolymers,
which aims to minimize the implications associated with currently reported systems such
as stability loss and limited efficiency for post-modification. The new material design
involves simple synthesis and accessible reactive group present on the surface, which can
be easily functionalized with ligand functionalities. The easy preparation and capabilities
for post-modification provide great potential to be used as delivery vehicles.
When translating nanoparticle-based biomedical imaging and therapy, one big obstacle is
the poor selectivity of these materials in vivo due to off-target localization. To address this
issue, In chapter 5 we come up with a simple material design that are available to mask cell
interactive functionalities on nanogel during circulation and then restore nanogel-cell
interaction by revealing the presence of these surface functionalities at a target site. These
nanogels with triggerable variational properties can function as imaging agents, my success
on this project will push our work on step closer to industrial applications.
Transporting molecules across incompatible interfaces is a significant challenge, especially
for globular proteins with large hydrophilic surfaces. If we could transport enzymes into
an organic phase without disrupting the structure and functions of these enzymes, it would
raise up a broad range of applications such as catalysis and sensing. To combat this problem,
I developed a novel and simple supramolecular approach in chapter 6, with which we were
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gratifying to find that not only the proteins can be easily shuttled from aqueous phase to
organic phase, their structures and functions are well maintained. Another achievement is
that specific protein from mixtures can be selectively extracted by introducing ligand into
the materials. These exciting findings from my project open up new possibilities for
application of supramolecular assemblies in sensing, diagnostics and catalysis.
Following the findings in chapter 6, we use specifically engineered interactions between
a polymer assembly in the apolar organic phase and a protein as the driving force to
transport the protein that was originally present in the aqueous phase in chapter 7. By
crosslinking the reverse micelles in the organic phase, we could introduce new size-based
selectivity in enzymes. Controlling substrate accessibility to the core of the nanoreactor
can expand the system to function in a more complex environment, where a mixture of
substrates is present.
8.2 Future directions
8.2.1 Unnatural silectivity in enzyme nanoreactor
Controlling substrate accessibility to the core of the nanoreactor can expand the system to
function in a more complex environment, where a mixture of substrates is present. With
this reverse micelle scaffold, we can introduce new substrate selectivity in enzymes, which
are known to be inherently promiscuous. We hypothesize that crosslinking the reverse
micelles in the organic phase would affect the substrate permeability into this aggregate,
which should introduce size-based selectivity. We will test this permeability using a series
of substrate molecules that contain the same enzyme-sensitive functional group, but with
systematic variations in molecular weights of the substrate molecules (Scheme 8.1a).
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Scheme 8.1 Structures of substrates with varied molecular weight for enzyme nanoreactors

To further investigate the impact of the crosslinking-based selectivity in these assemblies,
we will also test the catalytic function using amphiphilic substrates to delineate the effect
of hydrophobicity that could affect the inherent accessibility to the interior of nanoreactors.
The proposed structures are shown in Scheme 8.1 b.
It is also reasonable to expect that crosslinking density of the reverse micelles would alter
the substrate selectivity. To investigate this possibility, we will systematically vary the
extent of DTT crosslinker addition and assess change in substrate selectivities in these
assemblies.
Unifying the lessons from these Aims will provide robust design guidelines for the next
generation of enzyme nanoreactors for performing biocatalysis in apolar solvent, with
capabilities that do not exist at this time. In addition to bringing the high catalytic fidelity
of nature’s catalysts as an enabler in organic synthesis, these design guidelines will also
open up new possibilities for versatile applications such as on-demand release, point-ofcare catalysis, sensing and drug delivery.
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8.2.2 Switchable catalytic reactions in the reverse micelles
Triggerable materials have been extensively explored for various applications such as
controlled release and sensing, because their response can be turned ‘on’ by certain
stimulus.1-6 Inspired by the opportunities such triggerable materials offer, we are interested
in identifying opportunities to effectively regulate reaction processes and behaviors with
external stimuli by simply controlling the timepoint to switch the nanoreactors ‘on’ and
‘off’. For this purpose, we design a light triggerable enzyme nanoreactor that can perform
on-demand catalytic function in apolar organic solvents. Light as the catalysis-controlling
agent is particularly appealing, since it offers a non-contact, extrinsic control and can be
delivered instantaneously to the whole system without any diffusion limitations that are
inherent to chemical and thermal deliveries. Additionally, its operational convenience and
temporal control over the light irradiation time and intensity can improve the practical
potential of the light-responsive catalytic system enormously.
(a)

Organic phase

+
Crosslink (UV 365 nm)

Decrosslink (UV 280 nm)

Nanoreactor “ON”

Nanoreactor “OFF”

(b)

Figure 8.1 (a) Schematic representation shows triggerable switch for turn ‘on’ and ‘off’ of
the nanoreactor. (b) molecular design and reversible crosslinking chemistry reaction using
coumarin.
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Here we choose coumarin as the hydrophobic moiety, which is also crosslinkable.
Coumarins can undergo a 2+2 photo-dimerization upon irradiations at l > 300 nm, whereas
the reverse photo-scission reaction occurs under irradiation at l < 300 nm.7-8 We will
choose the crosslink densities, using the lessons learnt from the sub-Aims above, such that
these assemblies do not allow substrate molecules to enter the lumen of the assembly when
crosslinked. In this scenario, we can indeed regulate the accessibility of certain substrate
to enzyme and thus control the reaction by crosslinking or decrosslinking the reverse
micelle systems (Figure 8.1).
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